1 FRONT MATTER

2

3

4 5

6 7 Infection control strategies in essential industries: using COVID-19 in the food industry to model economic and public health trade-offs

Short title: Infection control trade-offs

8 Authors

9 Christopher Henry¹, Ece Bulut¹, Sarah I. Murphy¹, Claire Zoellner², Aaron Adalja³, Diane

Wetherington⁴, Martin Wiedmann⁵, Samuel Alcaine⁵, Renata Ivanek^{1*}

12 Affiliations

¹Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine,
 Cornell University, Ithaca, NY, USA

- ¹⁵²iFoodDecisionSciences, Seattle, WA, USA
- ¹⁶ ³Nolan School of Hotel Administration, Cornell SC Johnson College of Business, Cornell
- 17 University, Ithaca, NY, USA
- ⁴iDecisionSciences, Seattle, WA, USA
- ¹⁹ ⁵Department of Food Science, College of Agriculture and Life Sciences, Cornell University,
- 20 Ithaca, NY, USA

21 22

*Corresponding author: Renata Ivanek ri25@cornell.edu

23 24

25 Abstract

The COVID-19 pandemic exposed challenges of balancing public health and economic goals of 26 infection control in essential industries like food production. To enhance decision-making during 27 future outbreaks, we developed a customizable agent-based model (FInd CoV Control) that 28 predicts and counterfactually compares COVID-19 transmission in a food production operation 29 under various interventions. The model tracks the number of infections as well as economic 30 outcomes (e.g., number of unavailable workers, direct expenses, production losses). The results 31 revealed strong trade-offs between public health and economic impacts of interventions. 32 Temperature screening and virus testing protect public health but have substantial economic 33 downsides. Vaccination, while inexpensive, is too slow as a reactive strategy. Intensive physical 34 distancing and biosafety interventions prove cost-effective. The variability and bimodality in 35 predicted impacts of interventions caution against relying on single-operation real-world data for 36 decision-making. These findings underscore the need for a proactive infrastructure capable of 37 rapidly developing integrated infection-economic mechanistic models to guide infection control, 38 policy-making, and socially acceptable decisions. 39

- 39 40
- 41 Teaser

42 COVID-19 model helps navigate trade-offs between public health and economic impacts 43 of infection control interventions in essential industries.

44

45 MAIN TEXT

46

47 Introduction

The United States (US) food industry, known for its labor-intensive nature (1), was 48 significantly affected by the Coronavirus disease 2019 (COVID-19) pandemic, alongside other 49 essential industry sectors (2). During the early phases of the pandemic, food facilities/operations 50 abroad and in the US were forced to close or reduce production due to labor shortages (2, 3). US 51 52 livestock processing, including poultry, pig, and cattle slaughter, was reduced by up to 45%, resulting in job losses, financial impacts, retail shortages and loss of animals (4, 5). During the 53 COVID-19 pandemic in 2020, the combined value of production for beef, pork, broilers, turkeys, 54 eggs and milk was reduced down by \$12.8 billion in the US, to 9% below the pre-pandemic 55 forecast for 2020, based on price and production quantity projections (6). Dairy supply chain 56 disruptions caused increased milk dumping in the US, where 2.5% of all federally regulated milk 57 was dumped compared to 0.2-0.5% dumping recorded in the normal course of production (7). By 58 59 September 2021, nearly 100,000 workers in US meatpacking facilities, food processing facilities, and farms were reported positive for COVID-19, most of which were from meatpacking facilities 60 (65%) and other food processing facilities (21%) (8); importantly, these statistics are likely 61 underestimates (9). These outbreaks drove infection rates in rural communities, as individuals 62 infected at work transmitted their infection to others outside of work (10). By the end of 2020, 63 COVID-19 cases attributable to meatpacking facilities were reported to be the source of an 64 65 estimated 334,000 infections in the US, with associated mortality and morbidity costs totaling more than US\$11.2 billion (11). These impacts affected the functioning of the national food 66 67 supply chain.

Several mitigation strategies have been considered, encouraged, or enforced to control the 68 spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the US food 69 industry (12, 13). These control strategies include vaccination, practicing physical distancing, use 70 71 of face coverings, screening for infection, practicing personal hygiene (e.g., hand washing), cleaning and disinfection of the working environments, ventilation improvements, and 72 minimizing community spread. Produce (i.e., fruit and vegetable) farms and food processing 73 74 facilities, while having certain features in common, vary greatly in size, physical characteristics, and organizational structure (14). Thereafter, for brevity, we use 'operation' when referring to any 75 individual produce farm operation or food processing facility. Food operation's varying locations, 76 77 policies, and workforce demographics have resulted in significant differences in worker histories with respect to vaccination, boosting, and past infection (15, 16). The diversity of operations and 78 mitigations have led to strong interest from industry stakeholders in modeling tools tailored to the 79 particular characteristics of their individual operations (17) to aid them in making predictions, 80 81 such as regarding the expected outbreak dynamics and impacts of possible interventions, and decisions, such as what level of investments to make in biosafety measures or when to start or 82 stop an intervention (personal communication with the Industry Advisory Council for the study). 83 Importantly, the evaluation of COVID-19 mitigation strategies should be based not only on public 84 health metrics but also on economic metrics that account for the production losses in the operation 85 due to worker shortages or strict infection control strategies, as well as considerations of negative 86 87 societal impacts of food supply chain disruptions and possible food shortages. Several mathematical models (18-30) have been developed to evaluate and compare 88

89 COVID-19 mitigation strategies and assess their effectiveness across different levels of

20 compliance. These models are primarily designed for national scale assessments (21, 25-27) but

also include more localized communities, encompassing cities (24, 28, 30), closed societies with

shared environments (19, 29), and even smaller communities in universities (22), companies (20,

23), and office spaces (18). Some of the evaluated interventions include physical distancing, mask
 use, vaccination, asymptomatic/symptomatic testing, contact tracing, quarantine, restrictions on

2

travel, isolation, and school closures (18, 19, 26-28). While most of the modeling studies 95 96 concentrate on health outcomes in the general population, only a handful have considered the health of individuals within workplace settings. These settings include a generalized company 97 building (20), an oil and gas facility (23), a meatpacking plant (29), and a university building 98 (22). These studies have accounted for the complex process of disease transmission between 99 individuals by using agent-based models (ABMs), which can simulate employees' decisions based 100 on their social and physical profiles. A few studies have also utilized ABMs to simulate the 101 102 economic impacts of COVID-19 (24, 25, 30, 31). Nevertheless, there remains a need for models that explore COVID-19 spread as well as the health and economic impacts of mitigation strategies 103 in individual food operations to help prevent similar impacts in future infection outbreaks. 104 Here, we provide Food Industry CoVid-19 Control Tool (Find CoV Control), a 105 customizable tool based on an ABM developed to simulate COVID-19 transmission dynamics in 106 the food industry work environment. We integrated the ABM with an economic model to predict 107 108 the direct and (certain) indirect costs of interventions. Using COVID-19 in the food industry workforce as a model system, our objective was to develop a tool that helps policymakers and 109 individual operations navigate tradeoffs between public health and economic impacts of infection 110

111 control interventions in an essential industry.

- 112
- 113
- 114
- 115 **Results**

116 Model setup

117 FInd CoV Control consists of three modules: Employee population, Work environment, and Disease transmission (Figure 1A; definitions in Text S1, further details in Texts S2-S4 and 118 **Tables S1-S13**). The Employee population includes all employees (agents) in a modeled 119 120 operation, each of which is characterized by a set of attributes (**Table 1**). The Work environment module defines the characteristics of the work environment in terms of a produce farm or 121 processing facility setting (thereafter referred to as 'farm' and 'facility' for brevity), shift schedule 122 (Figure 1B.i), and agent hierarchy and contact network (Figures 1B.ii, 1B.iii, and S1). The 123 Disease transmission module tracks COVID-19 infection spread in a population representing 124 employees of a operation, using an elaborated variant of a "Susceptible-Exposed-Infectious-125 Recovered-Susceptible" (SEIRS) model (Figure 1C). FInd CoV Control is customized to the 126 population and work environment of a particular operation based on the user-set parameters 127 (**Table 2**), which are also used to calculate the number of agents with various immunity 128 trajectories and histories (Table 3). We used FInd CoV Control to make predictions about 129 COVID-19 transmission dynamics following the arrival at work of an index case infected outside 130 the workplace, both under a no-intervention "baseline" and under various interventions. The 131 evaluated interventions included: a temperature screening intervention, three virus testing 132 interventions, a total of five primary vaccination and/or boosting-promoting interventions, and 133 three direct basic reproduction number (R_{θ})-reduction (physical distancing and/or biosafety) 134 interventions (Figure 1A). The baseline and interventions were simulated in a way that allows 135 counterfactual comparisons. Interventions were evaluated using two groups of metrics: (i) Public 136 health: the number of employees with symptomatic and asymptomatic infection (and total 137 infected); and the initial effective reproductive number $(R_{eff.})$ and (ii) Economic: the number of 138 employees unavailable to work; the fraction of shifts with employee shortage; and total direct 139 expenses, production losses, and total costs associated with an intervention (expressed in US\$) 140 (Figure 1C). While economic effects are often interrelated and ripple over multiple dimensions, 141 142 in FInd Cov Control, the economic analysis is limited to the costs directly borne by operations

(Text S5) and is meant to serve as a reference, together with the infection model, for employers'
 decision-making.

145

146 Model validation

FInd CoV Control was validated with publicly available data on outbreaks from early in 147 the pandemic when few, if any, interventions would have been implemented. Specifically, for 148 produce farm operations, FInd CoV Control was validated using two outbreaks, one on a farm 149 with shared (i.e., employer-provided dormitory style) housing and one with a mix of shared and 150 individual housing. For processing facilities, FInd CoV Control was validated using three 151 outbreaks in facilities with individual housing, one in each of the dairy, pork, and produce 152 processing facilities. These outbreaks and validation results are described in **Text S6**. The results 153 of the validation analysis indicated a reasonable fit between the reported data and model 154 predictions. 155

156

157 Main results

We begin by presenting a representative set of results over a 90-day simulation, for a 158 facility with 103 employees, shared housing, and otherwise default parameters (see **Tables 2** and 159 4), in Figures 2, 3, and 4. Results for the farm model with similar parameters are qualitatively 160 comparable, and outcome estimates for a larger facility with 1,003 employees (Figures S2, S3 161 and S4) are generally similar with the main differences being later-peaking outbreaks (due to 162 163 greater incidence growth required to saturate the larger population), and an associated modest increase in the effectiveness of some interventions. There is also a modest reduction in noisiness, 164 which leads to a reduction in the probability of experiencing labor shortages in individual runs, 165 given that the average outcome is not to experience a shortage in either case. Differences 166 associated with shared versus individual housing are covered in the "Scenario analysis" section 167 (and Text S7). 168

Results pertaining to the number of symptomatic infections, our primary public-health outcome, are presented in **Figure 2**. There is little qualitative difference between the curves depicting the mean incidence (**Figure 2A**) and mean prevalence (**Figure 2B**) of symptomatic infection over time, although there is a difference in scale and a slight difference in location (with peak incidence occurring slightly prior to peak prevalence) and noisiness (with more visual noise in the incidence vs prevalence curves). This result is expected, so to avoid redundancy, we focus on (cumulative) incidence in the remaining panels.

176

177 Bimodality and variability in symptomatic infections

For all interventions (including the no-intervention baseline), over 40% of all runs result in no symptomatic infections at all (**Figure 2C**), and as a result, the number of symptomatic infections for a given intervention is strongly bimodal at baseline and for all interventions except for moderate viral testing (p = 0.3, i.e., 30% of scheduled workers tested each shift, amounting to testing every worker 1.5 times per week), high-intensity viral testing (p = 1, i.e., every worker scheduled for testing each shift), and "high-effectiveness (-80% R_0) Physical

distancing/Biosafety" (**Figure 2D**). This reflects that, in the absence of repeated reintroduction from the broader community, a major source of variance is the possibility of early stochastic dieoff, even at an initial R_{eff} well above 1 (e.g., $R_{eff} = 2.52$ at baseline for this scenario), which

effectively partitions the vast majority of outcomes (for interventions for which R_{eff} remains

appreciably above 1) into two modal regions (groups) with respect to the outbreak size: (i) small $\frac{1}{2}$

- or non-existent outbreaks and (ii) large outbreaks. At baseline, over the 90 days since the
- introduction of an index case, group (i) has 0-12 (median 0, mean 0.60) total infections, not
- including the index case, and 0-4 symptomatic infections (median 0, mean 0.16), with no infected
- individuals left by the end of simulation, while group (ii) has 51-97 total infections (median 82,

mean 81.9), not including the index case, and 17-49 (median 34, mean 33.1) symptomatic
infections. There are also 5 runs (out of 1000) that fell between these two groups, with 21-42 total
infections (median 39, mean 35.8) and 5-14 symptomatic infections (median 11, mean 10.6).

196

197 Bimodality and variability in counterfactual effects of interventions

We can refine and expand observations detailed in the previous section by taking 198 advantage of the steps we have taken to make counterfactual comparisons as precise as possible 199 200 (see "Interventions" section); specifically, the *i*-th run of the model with any intervention corresponds in a meaningful way to the *i*-th run of the model at baseline, with the difference 201 between the two being attributable solely the intervention. Consequently, it is meaningful to 202 examine the pairwise differences, with respect to a particular outcome, between corresponding 203 runs with and without a given intervention. The distributions of these pairwise differences, for 204 runs that have at least one symptomatic infection at baseline, are presented in **Figure 2E**. There, 205 we can see that there is not only a great deal of variance in outcomes within an intervention (or 206 within the baseline), but also a substantial variance in the counterfactual effects of an 207 intervention. This is meaningful, considering that the individual ABM runs reflect the real-world 208 variation in epidemiologic outcomes, and the model provides a view into the counterfactual 209 comparisons within individual runs that cannot be observed in the real world. To illustrate this 210 phenomenon, a single intervention can be examined in detail (Figure 2E). The "moderate-211 effectiveness (-40% R_0) Physical distancing/Biosafety" intervention is modestly beneficial on 212 average (mean reduction in number of symptomatic infections = 10.4) and in its typical 213 performance (median reduction = 6). Nevertheless, it can be extremely effective in individual runs 214 (maximum reduction of 45, close to the maximum across all interventions of 48). On the other 215 hand, it can prove entirely ineffective or even counterfactually *counterproductive* in other 216 individual runs (61 runs with no reduction in number of symptomatic infections, and 68 runs with 217 an *increase* of 1-20. This is due to the timing and chance effects as explained in **Text S8**, where 218 results for additional interventions (temperature screening and viral testing) are also illustrated. 219 We can also note that most of these distributions of pairwise differences are themselves bimodal, 220 reflecting two different ways that an intervention can counterfactually affect a run that produces 221 large outbreak in the no-intervention scenario. In these counterfactual comparisons, on the one 222 hand, an intervention may prevent a large outbreak altogether, producing a data point in the high-223 effectiveness modal region in Figure 2E (and contributing to the difference in the number of 224 large outbreaks between the intervention and no-intervention scenarios in Figure 2D). 225 Alternatively, it may produce a smaller difference in the outbreak size (or none at all), producing 226 a data point in the low-effectiveness modal region (and still contributing a large outbreak to both 227 228 the intervention and no-intervention scenarios in Figure 2D). Depending on the intervention, one of these modal regions may be extremely small, or they may both be substantial. 229

We can further refine these observations by considering the change in number of 230 symptomatic infections as a fraction of the baseline number of symptomatic infections (Figure 231 **2F**; **Figure S2F** for a large facility). In particular, for those interventions with a significant 232 fraction of runs in the high-effectiveness modal region, the primary way that they shift runs from 233 having large outbreaks in the no-intervention scenario, to not having large outbreaks in the 234 presence of the intervention is, by causing them to have no symptomatic infections at all; the 235 apparently symmetrical lower modes seen in **Figure 2E** are primarily produced by variation in the 236 number of infections (in a *large* outbreak) at baseline, not by variation in the number of infections 237 (in a small or (effectively) non-existent outbreak) under the intervention. 238

240 "All good things in moderation" may backfire in viral testing

239

Based on the different patterns of effects in **Figure 2F**, the most effective reductions in symptomatic infections are seen for moderate- and high-intensity viral testing. **Figure 4** (**Figure**

S4 for a large facility) shows that viral testing at a fairly high rate is also generally more costly. In 243 the case of high-intensity viral testing, this cost is overwhelmingly due to direct intervention 244 expenses (primarily the cost of test kits), and this result is robust across a variety of scenarios (not 245 shown). This is also true in most runs for moderate-intensity viral testing, but in some runs, 246 moderate-intensity viral testing can result in significant costs due to both direct intervention 247 expenses and production losses. The latter reflects the ability of testing at a "moderate" rate 248 (p=0.3/working day) to generate a "worst of both worlds" scenario. This scenario generates large 249 250 numbers of employees who are isolated at the same time, resulting in large numbers of workershifts missed due to isolation, yet, infected employees are not identified and isolated fast enough 251 to prevent a large outbreak from occurring. A more frequent version of this (rarely producing > 252 15% absences on a production shift, which is considered to cause shortages and, thus, production 253 losses) can be seen for low-intensity viral testing (p = 0.05/work day) where mean and median 254 increases in unavailability are both greatest (Figures 3E and 3F; Figures S3E and S3F for a large 255 256 facility). This observed pattern reinforces and extends the result from prior research that existent but inadequate larger-scale (city-level) non-pharmaceutical interventions can result in what the 257 authors describe as a "dual blow of increased deaths and unemployment," which fall 258 disproportionately on low-income workers (30). 259

260

261 Health benefits of physical distancing/biosafety interventions at low cost

Finally, the next-most effective intervention in preventing symptomatic infections, after 262 the moderate- and high-intensity viral testing interventions is the "high-effectiveness (-80% R_0) 263 Physical distancing/Biosafety" intervention (Figure 2F), for illustration purposes represented by a 264 combination of masking, face shield use, and ventilation improvements. We found this to be 265 much more effective than the "moderate-effectiveness (-40% R_0) Physical distancing/Biosafety" 266 intervention (represented by masking and face shield use, without ventilation improvements), but 267 only modestly more costly (and substantially less costly than the more effective viral testing 268 interventions) (Figure 4). 269

270 271

272 Scenario analysis

For our scenario analysis, we first defined several elements whose effects and interactions 273 with intervention effects we wished to examine (Figure 5). These scenario elements were 274 "setting" ("farm" vs. "facility"), "housing" ("individual" vs. "shared"), "vaccinated" ("high" 275 (based on US national levels in early 2022 (32,33)) vs. "none"), and "recovered" ("high" US 276 national levels (32, 34, 35) vs. "none") (details in section Text S7 and Table S12). We then 277 conducted a full factorial analysis for all 16 combinations of these four factors (and for all 13 278 intervention scenarios) in the default facility size of 103 workers over 90-day-long simulation 279 runs. Many combinations of these scenarios are intended to represent limiting cases, rather than 280 realistic scenarios, e.g., a scenario with both "vaccinated" = "high" and "recovered" = "none" 281 represents a limiting case of relatively high vaccination and no history of infection. Results of this 282 283 analysis, evaluated using regression trees for each of the three primary outcomes (symptomatic infections, worker-shifts unavailable, and total cost) and the two separate contributors to total cost 284 (production losses and intervention expenses), indicated that, for outcomes other than production 285 losses, the effects of "setting" were relatively limited, and mostly pertained to which other effects 286 were strong enough to be included in the pruned partition trees. Because transmission in the two 287 settings is defined by the user-settable value of R_{θ} (**Table 2**), which was kept the same between 288 289 the two settings, the observed differences between settings can be attributed to differences in the work environment (Figures 1B and S1). In general, the evaluated outcomes were slightly higher 290 for the "facility" setting than for the "farm" setting. Because of this, and to omit explanations of 291 the different equations used to set default production-per-week in the two different settings, we 292

chose to describe results from the facility model here. Because total cost is simply a sum of
intervention expenses and production losses, and because various factors affect each of those
components differently, we will focus our discussion on each cost individually (results presented
in Figure 5).

297

Health and economic outcomes are driven by the interaction between the worker infection history and intervention intensity

For almost all evaluated outcomes, the two biggest factors driving outcomes are intensity 300 of virus testing intervention and "recovered" (i.e., whether the employee population has a 301 significant history of natural infection) (Figure 5); the only exception is intervention expenses 302 (Figure 5C), for which intensity of virus testing was the strongest factor, but "recovered" did not 303 produce a sufficient impact to appear in the regression tree. While "recovered" being "high" 304 (rather than "none") had a desirable impact (i.e., produced lower symptomatic infections, 305 unavailability, and intervention expenses) on all outcomes for which it was relevant, the effects of 306 virus testing were more variable. Symptomatic infections are minimized by viral testing at a rate 307 308 high enough to reliably control an outbreak before it can get large (testing every worker every shift or roughly every 3 shifts (p = 1 or 0.3/ work day, respectively)) (Figure 5A). Unavailability 309 (Figure 5B), on the other hand, is lowest when *either* testing is non-existent (and so no workers 310 are isolated as a result of testing, but only as a result of hospitalization) or testing is extremely 311 intensive (and so the outbreak(s) is/are rapidly contained; p = 1/work day); however, even such 312 intense testing may be insufficient to achieve a reasonable level of control in the face of a 313 314 population with insufficient natural and hybrid immunity ("recovered" = "none") and constant reintroduction (housing = "individual"). Conversely, unavailability is *highest* when the testing 315 rate is intermediate (p = 0.05 or, even more so, p = 0.3/work day), resulting in enough 316 asymptomatic and mildly symptomatic cases being detected to increase unavailability, but not 317 enough to rapidly contain the outbreak(s). Similarly, production losses (which are driven by 318 unavailability of $\geq 15\%$ on a production shift) are highest when p = 0.3/work day, to the point that 319 recursive partitioning with default parameters results in further division only of the node with p =320 0.3; all scenario-intervention combinations with either a lower (p = 0, p = 0.05) or a higher (p = 1) 321 rate of virus testing are combined in a single node (Figure 5D). Intervention expenses, on the 322 other hand, move in an opposite pattern to symptomatic infections, and are highest when the rate 323 of viral testing per work day is highest (p = 1), and lowest when it is low (p = 0.05) or non-324 existent (p = 0) (Figure 5C). 325

326

327 Strongest outcome drivers are viral testing intensity and history of natural infection

While "recovered" is consistently more important than "vaccinated" (i.e., splits defined by 328 it occur closer to the root of each tree, where either occurs at all), and both share a uniformly 329 330 desirable effect (where they show any effect at all), the interaction of the two is more complex: For production losses, there is only a split defined by "vaccinated" in a branch in which 331 "recovered" is set to "none," but for symptomatic infections, the reverse is true – the only split 332 333 defined by "vaccinated" occurs in a branch in which "recovered" is set to "high." In more conceptual terms, this amounts to saying that, at the population level, immunity resulting from 334 recovery from natural infection plays a stronger role in determining a wide range of simulation 335 outcomes than immunity resulting from vaccination - perhaps an unsurprising result late in a 336 pandemic; whether the interaction of these two is sub-additive or super-additive depends on 337 which outcome one is considering. In particular, with respect to symptomatic infections, there 338 339 may be a synergistic effect of vaccination and recovery from natural infection, likely reflecting the strong protective effect of modeled hybrid immunity. For production losses, on the other hand, 340 vaccination is less influential in the presence of moderate-to-high levels of natural recovery 341 within the past year. This likely reflects the threshold effect in our model of production losses (of 342

15%) - in the presence of sufficient protection from natural recovery, the probability of suffering
 production losses at all may be low enough, even in the absence of vaccination, to reduce the
 importance of vaccination in predicting or determining that outcome.

The only panel from which the "recovered" factor is absent, or even not one of the two 346 strongest factors, is **Figure 5C** Intervention Expenses; the "vaccinated" factor is absent from this 347 panel as well (although the cost of giving workers time off for vaccination is accounted for). This 348 is unsurprising, given that intervention expenses are driven far more - at least, for the relatively 349 350 simple interventions that we consider in this analysis - by what interventions one decides to implement than by transmission dynamics; as a result, no scenario parameters appear in it. The 351 only split that does, other than the virus testing splits, is a split by whether there is a Physical 352 distancing/Biosafety (" R_0 reduction") intervention, which raises costs (mean cost = US\$7,171 vs. 353 US\$1,108; Text S5) over the alternative (a weighted average of no-intervention baseline, 354 temperature screening, and vaccination and/or boosting interventions), in line with what we 355 356 would expect. Temperature screening, being similar in certain respects to virus testing, but substantially cheaper and generally substantially less effective, appears only in the tree for 357 unavailability (Figure 5B), where its use increases unavailability, more than a maximal rate (p =358 1) of viral testing (117 vs. 85=(26+164)/2). 359

361 Intervention effectiveness is highly sensitive to the degree of community transmission

Housing affects both unavailability (Figure 5B) and number of symptomatic infections 362 (Figure 5A); both are higher when housing is "individual". This is not to say that "shared" 363 dormitory housing is a poorer environment for transmission than individual housing; rather, it 364 reflects the role of community transmission in creating opportunities for reintroduction of 365 infection from outside the employee population. This result is confirmed and elaborated by tests 366 in **Text S7**, where we treat presence or absence of community transmission and presence or 367 absence of dormitory transmission as separate factors. In line with this, additional analyses (Text 368 S7) further indicate that our predictions about intervention effectiveness can be highly sensitive to 369 the degree of community transmission. 370

372 "*R*₀ reduction" strategies are cost-effective

Physical distancing/Biosafety interventions (" R_0 reduction") can reduce the number of symptomatic infections (when sufficiently effective) with minor increase in intervention expenses (**Figures 5A** and **5C**, respectively). This suggests that highly effective R_0 reduction strategies are cost-effective and, hence, should be prioritized for implementation.

377 378

371

360

379 Sensitivity analysis

To test the sensitivity of our model to a variety of parameters that are not user-settable, we 380 visually and numerically examined the results when each of these parameters was varied, using a 381 One Factor at a Time (OFAT) approach, with all other parameters (both user-settable and 382 383 otherwise) at their default values, except that we examined a facility with "individual" housing. In this analysis, we focused on our three primary outcomes -- total symptomatic infections, total 384 number of worker-shifts missed, and total cost over the simulation length -- and, additionally, on 385 the employee-to-employee (contribution to the) effective reproduction number (R_{eff}) at the start of 386 simulation. In Figure 6, we present results for 5 representative intervention scenarios, for the 5 387 parameters that showed the greatest sensitivity across all evaluated parameter-outcome 388 389 combinations. For each of these parameters, we present the mean value for each outcome when the parameter is halved, when it is left (along with all other parameters) at its default value (**Table** 390 S14), and when it is doubled. Symptomatic infections are most strongly affected by parameters 391 defining the mean duration (μ_{IM}) of mild symptomatic infection and relative per-contact 392

probability of transmission (β_{IM}) during this stage), followed by a parameter (φ) governing the protection from developing symptomatic disease provided by Recovered and Hybrid immunity (**Text S8B**). Worker-shifts missed are most strongly affected by the relative frequency of severe infection, given any symptomatic infection (ψ), followed by the mean duration of severe infection (μ_{IS}), while the effects of these 5 parameters on R_{eff} and total cost were generally smaller (**Text S8C**).

- 399
- 400
- 401

402 Discussion

This study presents an ABM for tracking COVID-19 transmission and control in the food 403 industry workforce to serve as a decision-support tool that can be used to mitigate the impacts of 404 infectious disease outbreaks on essential worker populations and the food supply chain. The 405 model can be customized to produce farm or processing facility settings, the type of employee 406 407 housing predominantly used, as well as the vaccination and infection history and age characteristics of the workforce. Additionally, the model allows testing of a number of 408 interventions and evaluating them counterfactually with regard to several public health and 409 economic outcomes, and interpretation of predictions at the population and individual operation 410 levels. The two strongest themes in our results are bimodality and trade-offs. Finally, the model 411 also provides insights about effectiveness of different possible interventions and areas requiring 412 413 further research. The developed model is expected to facilitate the food industry's resilience and responsiveness to COVID-19 and similar future outbreaks, as well as to help navigate tradeoffs 414 between public health and economic impacts of infection control interventions in essential 415 industries. 416

417

418419 Bimodality and variability in outcomes and intervention effectiveness

The simulation runs of FInd CoV Control can be interpreted to represent a population of 420 operations with similar workforces and work environments. The simulation predicts how an 421 outbreak would unfold in each operation (i.e., run) following infection introduction, and in 422 counterfactual versions of the same operation that implemented different interventions. This 423 allows us to interpret the predictions at the population level, answering questions such as: "What 424 fraction of operations would experience certain health and economic outcomes?" Not only are 425 most outcome distributions bimodal, but the counterfactual effects of most potential interventions 426 are bimodal as well. Relatively ineffective (on average) interventions (e.g., temperature 427 screening) not only sometimes appear to produce good outcomes, but also genuinely produce 428 strong positive effects in a counterfactual sense, albeit with low probability. This is a particular 429 consequence of a broader phenomenon: Much of the positive effect (when there is one, and 430 especially when there is a strong one) of effective and ineffective interventions alike comes from 431 their potential to control an outbreak at a very early stage, often before there is a single 432 symptomatic infection. This presents a further challenge for "reactive" interventions (i.e., those 433 implemented after the detection of a first infected case), above and beyond the issue of how 434 quickly they can be deployed; by the time that operation managers (or policy-makers) are aware 435 of an outbreak, the best opportunity to control it has already passed. This further supports the 436 value of tools like FInd CoV Control that can be used as planning/forecasting tools, perhaps 437 quarterly or on a rolling 90-day basis, to proactively prepare for the potential disease introduction. 438 Conversely, even fairly effective (on average) interventions can result in little or no effect 439 440 in individual outbreaks. Some may even be capable, albeit with low probability, of producing counterfactually worse outcomes. This can largely be attributed to matters of timing of infection, 441

for individuals who are infected at some point in either case; this can have an impact both through 442 chance occurrence of opportunities for secondary transmission at particular points in time, and 443 through the increase in probability of symptomatic infection that comes with increased time since 444 last immunity event (i.e., last vaccination or last recovery from natural infection). Together, these 445 possibilities, reflected in the bimodality in outcomes, further increase the (already substantial) 446 real-world probability of misleading conclusions from anecdotal observations in individual 447 operations, and thereby reinforce the importance of mechanistic, predictive models such as FInd 448 449 Cov Control. As an alternative, data-driven evidence-based recommendations would require large-scale data collection, including time-series information on the infection spread and control 450 (e.g., incidence of symptomatic and asymptomatic infections, results of diagnostics tests, 451 vaccination history, infection, and isolation-related absence from work). Importantly, the data 452 collected would need to include detailed metadata that explain the context of infection spread and 453 control in individual work environments, because the characteristics of the work environment 454 may serve as effect modifiers on the infection dynamics and intervention effectiveness. There are 455 limited examples of studies of COVID-19 epidemiology in the food industry work environments 456 (36, 37). These studies highlight the potential for rapid transmission of SARS-CoV-2 in the food 457 industry's work settings, which they attributed to the close arrangement of workstations and 458 extended contact among employees. The data made available by the food operations where the 459 investigations took place played a crucial role in enabling these studies. Our findings emphasize 460 the need for much larger-scale data collection. However, given the cost, technical, and 461 confidentiality-related obstacles to collecting such data, the prospect of purely data-driven 462 decision-support models is dim. Collecting confidential data on infection spread in a food 463 operation for the operation's private decision-making is of course encouraged. However, it should 464 be noted that in isolation from data on infection transmission in other comparable operations, such 465 data will have a limited value even for the operations' private use since the data will represent just 466 one of many possible ways an outbreak (with or without an intervention) has unfolded as 467 demonstrated by the model simulations. This underscores the need to proactively develop 468 infrastructure capable of rapidly building and analysis of mechanistic or hybrid (e.g., combining 469 ABM and machine learning (38)) models to guide infection control and policymaking under 470 471 urgency and sparse data conditions.

472 473

474 Tradeoffs between health and economic impacts of interventions

One of the biggest trade-offs we see in our results is that of cost vs. effectiveness, 475 476 particularly with respect to viral testing. Sufficiently intensive testing is highly effective at controlling transmission, but viral testing can be quite expensive, whether from the cost of test 477 kits themselves, the cost of increased unavailability due to isolation of individuals who test 478 479 positive, or both. Importantly, the intuitive solution of trying to find a moderate level of testing that optimizes this tradeoff is not necessarily a productive approach-testing, but at an 480 insufficient frequency to achieve reliable control can actually be more expensive than either more 481 frequent testing or not testing at all. The level of testing at which this economic "worst of both 482 worlds" occurs is one of multiple aspects of intervention effects that is heavily dependent on the 483 level of community transmission (modeled as individual housing that provided opportunity for 484 acquiring infection within the community), further complicating the effort to select an optimal 485 approach. It is helpful to realize the multiscale nature of infection control in work environments 486 deemed essential to society, where the interest is to control the infection and its effects at the 487 worker individual level (to protect the individual employee's health) and at the worker population 488 level (to reduce infection spread and cost of control, and increase labor availability). These scale-489 related trade-offs spill over into the trade-off between costs of control (borne primarily by the 490 company) and effectiveness (borne by both the company and individuals), leading to 491

inefficiencies commonly faced in the private provision of public goods (*39*). Designing public
health policies that align operation incentives with desired public health outcomes is therefore
critical to ensure the optimal provision of infection control interventions by operations. This
trade-off spills over into a broader challenge around both protecting essential workers and
supplying the country with food. Thus, there is a need for more discussion around essential
categories of industry and appropriate metrics for evaluating "costs of control".

498 499

500 **Cost-effectiveness of counterfactual interventions**

At an individual operation level, FInd CoV Control can be used preemptively to ask 501 questions such as: "Given the characteristics of the workforce and work environment in my 502 operation, if an infected worker enters my facility in the near future, how likely it is that we will 503 experience an outbreak?" "If we have an outbreak, how likely (in terms of the measures of central 504 tendency and variation) are health and economic impacts under different intervention scenarios?" 505 FInd CoV Control evaluates cost-effectiveness of 12 intervention scenarios and a no-intervention 506 scenario. As seen in Figure 2 and Figure 3, even intensification of vaccination in an already 507 moderately vaccinated population can yield modest but meaningful benefits. For proactive control 508 of COVID-19 in the food industry, maintaining a vaccinated and boosted workforce to be 509 prepared for a new outbreak remains a cost-effective intervention (albeit not sufficient to make 510 other interventions unnecessary). Vaccination uptake can be increased by removing convenience 511 and confidence barriers and leveraging workers' motivation to protect self, family, and 512 513 community (40). Our model findings seem to resonate with perceptions of the food industry's leadership. Certain companies, particularly those in the labor-intensive meatpacking sector, took 514 proactive measures by mandating vaccinations for their workforce (41-43) and prevented risk of 515 infection among employees and potential plant closures that were prevalent at the beginning of 516 the pandemic (44). In situations where vaccine mandates were not in place, other strategies such 517 as physical distancing requirements and quarantines were implemented; however, these 518 interventions were reported to lead to high worker absenteeism and hindered the efficient 519 operation of processing plants (1). Strategies like screenings for disease were valuable in 520 controlling workplace transmission, but also had serious limitations regarding reliability of the 521 results and posed challenges due to being labor-intensive and costly compared to simpler 522 strategies like use of face coverings and practicing personal hygiene (45). These observations in 523 the food industry match the findings in our model about the effectiveness of screening, testing and 524 physical distancing/biosafety strategies in preventing symptomatic cases, albeit with high 525 526 expenses and production losses associated with testing strategies. Effectiveness can also trade off against "costs" that are not strictly monetary. For example, even very intensive physical 527 distancing and biosafety measures may be cost-effective, but some aspects of such measures (e.g., 528 529 masking and face shields) can be highly unpopular in the long run (and even limit productivity in harsh work environments, such as extreme cold, hot and wet/damp), especially given the previous 530 observation of the limitations of *reactive* interventions (46). A comparison between the effects of 531 532 highly and moderately effective interventions in this category supports the idea that, if one is going to implement masking and face shields, the addition of ventilation improvements is likely 533 to be cost-effective. Our model revealed that predictions about intervention effectiveness are 534 highly sensitive to the degree of community transmission. This emphasizes the importance of 535 interpreting effectiveness of work-based interventions in the light of the epidemiology of the 536 disease in the community. This also emphasizes the importance of mitigating disease spread 537 outside of work; however, this is particularly challenging for agricultural worker populations that 538 are not stationary and typically share housing and transportation, allowing for easy employment-539 related transmission of the virus (47, 48). 540

541

542

543 Limitations and future directions

The empirical support for model parameter values varies, and this is of particular concern 544 for parameters identified as influential in the Sensitivity analysis (Figure 6). One area of 545 particular concern, given a combination of high sensitivity, moderate support (i.e., a good amount 546 of data, but somewhat coarse-grained, and with significant potential for confounding), and a 547 history of changing strains, is the magnitude of long-lasting immunity provided by boosting (e.g., 548 parameter φ), revealing that this is a critical knowledge gap requiring further research. Some more 549 structural limitations to our model include our relatively simple model of change in infectiousness 550 over the course of infection, our assumption that voluntary self-isolation is rare enough in 551 essential workers to be omitted from the model, our relatively simple model of vaccination and 552 boosting interventions (exponential decay of the eligible but unvaccinated/unboosted), and a 553 simplified binary notion of housing for a given operation as being either shared or individual. 554 There are numerous possible refinements of this model, many of which are facilitated to a greater 555 or lesser extent by its modular structure. Three areas seem particularly likely to be fruitful: (i) 556 557 Replacement of the current discrete-staged model of infectiousness over time with continuous infectiousness curves, analogous to the continuous curves that make up aspects of our continuous 558 immunity trajectories; (ii) Continued improvement of our model of immune effects, immune 559 boosting, and immune waning, as well as accounting for the changes in vaccination guidelines; 560 and (iii) Incorporating multiple simultaneous interventions (starting at different times) and 561 incorporating mixed individual and shared employee housing. More broadly, we hope to further 562 increase the modularity, flexibility, and ease-of-use of the model, to facilitate easy modification to 563 address other respiratory pathogens and/or other critical infrastructure sectors to enhance 564 resilience and responsiveness to similar future outbreak events. Towards these goals, we created a 565 user-friendly web interface for an early version of FInd CoV Control described in this article, 566 which allows the user to customize it to the characteristics of their workforce and generate a clear 567 and easily interpretable confidential result (49). 568

- 569 570
- 571
- 572 Materials and Methods

573 **Employee population module**

We model a heterogeneous population of agents (employees) with a variety of attributes reflecting both their current state and certain aspects of their personal history. Agent attributes set at the simulation start are summarized in **Table 1**. Attributes that represent past events and current state include age, (directly) immunity-related attributes, vaccination history, and the current state of infection, if any.

580 Age

579

585

Agents are randomly assigned an age category, with probabilities that are derived from industry-wide data about the age of agricultural workers (*50*). This age category is then used to determine their probabilities, in the absence of immunity, of experiencing symptoms or dying (**Table S1**).

586 *Immunity-related attributes*

In this model, all of an agent's attributes that are directly relevant to that agent's immunity, and that are not a consequence of their age, represent acquired immunity (whether complete or partial) to SARS-CoV-2 infection and COVID-19 disease. These attributes are associated with specific past events that created or boosted that agent's immunity; for ease of reference, we refer

to these simply as *immunity events* (**Table S2**). Thus, all agents had, conceptually speaking, an immune status of fully Susceptible (S) and a vaccination status of Not Vaccinated (NV, also referred to as unvaccinated) at the start of the COVID-19 pandemic, but some may have different values for one or both of these attributes at the start of the *simulation*.

Immunity-related attributes include the time $(t_{last, i})$ of the *most recent* immunity event, the 595 time $(t_{R,i})$ of the most recent recovery from natural infection (if any), an "immunity trajectory" 596 $(C_i, representing a trajectory defined by a combination of vaccination status and whether the$ 597 598 agent has previously recovered from natural infection), and what the agent's level of immunity was immediately prior to their most recent immunity event (P_{last, E, i}, P_{last, IP, i}, and/or P_{last, IS, i}) 599 (**Table 1**). Together, these determine an agent's Protection against Any Infection ($P_{E,i}$), Protection 600 against Symptomatic Infection given Any Infection ($P_{\rm IP + E, i}$), and Protection against Severe 601 Infection given Symptomatic Infection ($P_{IS | IP, i}$) at the present time (**Table 1** and **Text S3B**). Each 602 immunity trajectory includes curves for $P_{E, i}$, $P_{IP | E, i}$, and $P_{IS | IP, i}$. These may include an initial 603 increase in immunity, referred to as "ramp-up"; an initial period of total immunity; and/or 604 immune waning. During both ramp-up and immune waning, $t_{\text{last, i}}$ is relevant; during complete 605 immunity (for immunity trajectories R, HV1, HV2, and HB only), t_{R, i} is relevant (specifically, in 606 determining that there is complete immunity); and during ramp-up, P_{last, E, i}, P_{last, IP, i}, and/or 607 Plast, IS, i are also relevant. These attributes are discussed further in the section "Immune dynamics" 608 and in Text S3B and Tables S4-S7. 609

610611 *Vaccination History*

We assume for the sake of simplicity that all vaccination and boosting uses the monovalent Pfizer vaccine. Therefore, vaccination history includes the number of doses of vaccine the agent has received (i.e., whether they are unvaccinated (NV), partially vaccinated (V1), fully (primarily) vaccinated (V2), or boosted (B)), and when they received each of their previous doses, if any (**Figure 1B.iv**). Generally, only the time of their most recent dose is relevant to the model dynamics (**Table S4**). The current version does not account for repeated boosting in the vaccination history.

620 State of Infection

An agent's current infection status can be: Not Infected (NI), infected, but not yet infectious (E, for "Exposed"), Asymptomatically Infectious (IA), Presymptomatically Infectious (IP), Mildly symptomatic (IM), Severely symptomatic (IS), Critically symptomatic (IC), or Dead (D) (**Figure 1B.iv**). Additionally, if that state is anything other than Not Infected, we record how long they have been in that state; together with their precalculated duration (see below) for that state, this determines how much longer they will remain in it before progressing, recovering, or dying.

628

619

629 Initial setting of agent infection and vaccination history

Agents' history of immunity events prior to the start of simulation is important for 630 immunity (and immune ramp-up and waning), and their history of vaccination events specifically 631 is important for their eligibility for future vaccination (both primary and boosting). Therefore, 632 user input (**Table 2**), is used to determine what fraction of the population has and has not 633 experienced various immunity events and when. We then randomly generate exact times in a 634 simple fashion. This aspect of run initialization involves (i) current infection status initialization, 635 (ii) infection history initialization, and (iii) vaccination history initialization. These aspects do not 636 directly interact with each other, although infection history and vaccination history interact in 637 their effects on immunity. The initial settings are described in Text S2. 638

- 639
- 640

641 Disease transmission module

642 Course of infection

The main aspects of the course(s) of infection are summarized in Figure 1B.iv. Agents are 643 categorized as Not Infected (NI); Exposed (E); Infectious (I); or Dead (D). Infectious agents are 644 further divided by whether they currently have clinical disease (IA and IP vs. IM, IS, and IC), 645 whether they will subsequently develop clinical disease (IA vs. IP), and/or how severe their 646 symptoms are (IM vs. IS vs. IC). They are further categorized by their immunity trajectory – fully 647 Susceptible (S); one of the Vaccinated trajectories (V1, V2, or B); Recovered (R); or one of the 648 Hybrid (H) immunity trajectories (HV1, HV2, or HB) – and (for all immunity trajectories other 649 than S) the times since their last immunity event (their entry or reentry into that immunity 650 trajectory) and their last recovery, if any (see "Immune dynamics" section). 651

Infectible agents (i.e., agents whose infection status is NI, and whose susceptibility to infection (see "Transmission model" section) is greater than 0) can acquire infection with SARS-CoV-2 from a potentially infectious contact with an Infectious agent (i.e., IA, IP, IM, IS, or IC). The probability of such a contact resulting in an infection depends on the susceptibility to infection of the infectible agent $(1 - P_{E, i})$ and the infectiousness of the infectious agent (β_{IA} , β_{IP} , or β_{IM}). How contacts are made is described in the "Work environment module" section.

⁶⁵⁸ Upon infection, the formerly infectible agent enters the Exposed state (E), and after a ⁶⁵⁹ period of time ($D_{E,i}$), the Exposed agent becomes infectious (I). At this time, they enter one of ⁶⁶⁰ two states, both of which are continuously infectious, but without clinical disease: either IA or IP, ⁶⁶¹ the latter of which is the first stage of the symptomatic path. The distinction between IP and IA ⁶⁶² reflects a substantial difference in per-contact transmission rates between the two (*51*).

All IA agents are assumed to recover following a period of time $(D_{IA, i})$. Agents taking the symptomatic path progress through up to four stages: IP, IM, IS, and/or IC. All IP agents progress to the IM state after a period of time $(D_{IP, i})$, but agents who are in IM, IS, or IC may, after the corresponding period of time $(D_{IM, i}, D_{IS, i}, \text{ or } D_{IC, i}, \text{ respectively})$, either continue their disease progression to the next state on the symptomatic path or recover.

668 When an agent recovers, regardless of which infectious state they recovered from, their 669 last immunity event time ($t_{last, i}$) and Recovered immunity event time ($t_{R, i}$) are both set equal to the 670 current time, their infection status is set to NI, and their immune status is set to Recovered (R) if 671 they have never been vaccinated (NV), or to the appropriate Hybrid state (HV1, HV2, or HB) 672 otherwise. For agents in IC that do not recover, the next step is Death (D).

We do not explicitly model individual symptoms such as fever, cough, etc. However, for 673 the temperature testing intervention, we do tacitly assume that fever is only present if the 674 individual is symptomatically infected (IM, IS, or IC). We define "Severe" symptoms as those 675 requiring hospitalization; consequently, we assume that only agents with an infection status of IA, 676 IP or IM can transmit to their fellow employees, because agents with Severe or Critical symptoms 677 678 are so sick that they require hospitalization. Relative transmissibility (per contact) is set based on the infection stage (Table S3). Absolute transmissibility has no effect in the model, as we set the 679 average expected contact rate in order to achieve a specified basic reproduction number (R_0) , and 680 681 our assumptions about contacts per day (Text S3A) make the distinction between twice as high transmissibility per contact and twice as many expected contacts mathematically irrelevant. 682

683

For agents in any of the infected states, disease progression is based on the duration of each state
 (Table 4), age-dependent baseline probabilities of entering each disease state during disease
 progression (Table S1), and immunity-dependent modification of those baseline probabilities.

687

688 Transmission model

Agents who are infectible (i.e., agents whose infection status is NI, and whose
 susceptibility to infection is greater than 0) can be infected by contacts with either infectious

691 coworkers or infectious people outside of work, in the broader community (if housing is 692 "individual"). Contact structures of the agents while at work were determined by the place of 693 agents in the hierarchical structure of the farm or facility and their work schedule. To be more 694 precise, for each shift type (e.g., weekday Production Shift 1, weekend Cleaning Shift, etc.), we 695 have a matrix of expected contact rates between pairs of agents. For some combinations of a pair 696 of agents and a shift type, a non-zero contact rate may represent contacts made at work; for 697 others, it may represent contacts made in shared housing. Further details are in **Text S3A**.

698

699 *Immune dynamics*

We distinguish between 8 basic states (immunity trajectories) with respect to immunity: 700 fully Susceptible (S), partially vaccinated (i.e., with one dose of a two-dose primary series) (V1). 701 Fully Vaccinated (for the purpose of this study defined as a 2-dose primary series; V2), Boosted 702 (B), Recovered (R), and Hybrid immunity (H) with partial vaccination (HV1), with full 703 704 vaccination (HV2), or with full vaccination and a Booster (HB). Non-hybrid vaccinated trajectories (V1, V2, and B) feature a smooth ramp-up from their individual's previous level of 705 immunity, that lasts for $T_{V1\rightarrow V2} = 21$ days, $T_{ramp, V2} = 14$ days, or $T_{ramp, B, 1} + T_{ramp, B, 2} = 14$ days, 706 707 respectively, counting from the time since the individual's last immunity event (i.e., first vaccine dose, second vaccine dose, or booster shot, respectively). The non-hybrid Recovered trajectory 708 (R) features an initial $T_{\text{total, R}}$ = two months (61 days) period of total immunity, counting from the 709 time of their (most recent) recovery. The Hybrid immunity trajectories (HV1, HV2, and HB) 710 have characteristics of both vaccinated and recovered trajectories, and can be entered either by 711 recovery following vaccination or by vaccination following recovery. Consequently, a particular 712 individual's experience of one of these trajectories may include either or both of total immunity 713 and ramp-up. The transitions between these immunity trajectories are summarized in Table S2, 714 and the equations for the protection that they offer are given in **Table S7**. As evidence has 715 mounted that waning immunity, both from natural infection and from vaccination, plays an 716 important role in the dynamics of transmission during the pandemic, we included this in our 717 model. To take full advantage of the agent-based nature of our model, we assigned each agent 718 three variables indicating the major factors influencing their level of susceptibility to both 719 infection and progression: (i) the immune state that they entered at the time of their *last immunity* 720 event, (ii) the time at which that event occurred (and hence, at any given subsequent point in time, 721 how long it has been since that event), and (iii) the time of their *last recovery* from natural 722 723 infection. The exceptions are agents whose immune state is fully Susceptible (S), whose time of last event is not defined, and agents whose immune state is either fully Susceptible (S) or one of 724 the non-hybrid Vaccinated states (V1, V2, and B), whose time of last recovery is not defined. We 725 then created functions (Table S7) giving, for any valid combination of state, time since entry, and 726 time since recovery (and previous immunity, if they are currently in a ramp-up period), their level 727 of relative protection from each of infection, symptomatic infection conditional on any infection, 728 and severe infection conditional on symptomatic infection. We used exponential or exponential-729 mixture waning for long-term behavior of V2 and B (fitted from data in (52)), and logistic waning 730 for long-term behavior of R, HV1, HV2, and HB (with parameters inferred from the tables in 731 (53)), with some special case behavior at the start of states other than S (ramp-up and/or a period 732 of complete immunity), in order to account for the delay in reaching full protection following 733 vaccination, and to prevent unrealistic cycles of extremely rapid reinfection. This is further 734 explained in Text S3B. 735

736

737 General model of vaccination

Agents' vaccination status can be unvaccinated (NV), partially vaccinated (V1), fully vaccinated (V2), or boosted (B). This vaccination status directly corresponds to their immune status (with NV corresponding to fully Susceptible (S)) if they have never recovered from a

natural infection; if they have, then their immune status is either Recovered (R), if they have
 never been vaccinated, or one of the Hybrid immunity trajectories (HV1, HV2, and HB).

743

744 Vaccination trajectories

Partially vaccinated agents become eligible to receive a second shot $T_{V1} \rightarrow V2 = 21$ days 745 after receiving their first one, and fully vaccinated agents become eligible to receive a booster 746 shot $T_{V2 \rightarrow B} = 5$ months (treated as a deterministic 152 days) after their second shot (54). We 747 748 assume that all V1 agents enter V2 states as soon as they are eligible, but that only a fraction of V2 agents enters the B state as soon as they are eligible. We further assume that agents who are 749 eligible to become V1/B at simulation start, but have not yet done so, will not become V1/B 750 751 (respectively) during the simulation, in the absence of an intervention to promote primary vaccination/boosting, respectively. 752

753

754

755 Work environment module

In both farm and facility models, each week consists of 5 work days and 2 non-working days (i.e., a typical "work week" and weekend in the US). Each calendar day is modeled as consisting of 3 eight-hour periods we call "shifts." Each agent spends two shifts awake, and one asleep. For simplicity, we tie the agent's sleep cycle to their work cycle, so that each agent spends their first shift awake at work if it's a work day. This structure is illustrated for a sample agent (one scheduled to work on the first shift of the calendar day) in **Figure 1B.i** and shown in greater detail in **Table S8**.

In the facility model, each working day consists of Production Shift 1, Production Shift 2 (which may actually be a non-working shift, if the facility in question only has one production shift per day), and a Cleaning Shift. In the farm model, all agents are scheduled to work on the same shift, which, by analogy with the facility model, we refer to as Production Shift 1. (Hence, by the same analogy, all agents are awake, but not working, during Production Shift 2, and asleep during the shift that would be the "Cleaning Shift" in the facility model.)

We distinguish between available and unavailable agents for the purposes of SARS-CoV2 transmission between agents. Available agents are available to work their scheduled shifts –
meaning that they can do work (relevant in the economic analyses), and can also potentially
infect, or be infected by, other agents. Agents are available by default, but may become
unavailable to work (and, subsequently, may become available again).

In the baseline (no intervention) model, unavailable agents are limited to those who are either hospitalized (i.e., those who have an infection status of IS or IC) or dead (those who have an infection state of D). Hospitalized agents become available again upon recovery. Under certain interventions, agents who are not hospitalized may become diagnosed and isolated; these remain unavailable until they are deisolated (**Text S3C**).

We model a facility or farm with a hierarchical organization, although the details of this 779 hierarchy differ somewhat between the facility model and the farm model. This hierarchy is 780 781 assumed to be fixed over the time horizon of the model, as is the associated work schedule. The expected number of contacts between pairs of workers who are both "available" (i.e., not isolated, 782 hospitalized, or dead) is likewise held constant (i.e., we do not reassign workers between work 783 crews or production lines based on other workers' absences). To make the interface more 784 manageable, we assume that the structure of the operation is "regular" in the sense that if there are 785 two or more of the same sub-structure (e.g., two production shifts, two or more teams of work 786 787 crews, two or more work crews within a team, or two or more production lines), then each of those sub-structures has the same structural characteristics (e.g., if one work crew consists of 10 788 workers and a foreman, than all work crews consist of 10 workers and a foreman). 789

- Features specific to the farm and facility models are described in Text S4A and S4B.
 Briefly, we assume the following:
- All workers live in the same type of housing (i.e., either individual or employer-provided shared housing).
- All workers work a regular 40-hour, 5-day work week (8-hour shifts) and 2-day weekend,
 with the model simulation starting on a random day of the week, except for a small number of
 floating workers (e.g., quality assurance technician, mechanic) in the facility model, for whom
 the work shift(s) on a given day is/are randomly selected.
- There are many more contacts within the hierarchical structure than outside it (e.g., more contacts between workers on the same crew/production line than between workers on different crews/production lines, more contacts between foremen and supervisors than between other workers and supervisors, etc.), but that contacts are possible between any two agents who are both present on the same shift.
- All contact between workers occurs either (a) while traveling to, at, or traveling home from
 work, or (b) in shared, employer-provided housing, i.e., that workers in individual housing do
 not socialize with each other outside of work.
- There is homogeneous mixing within employer-provided housing.
- Worker contacts on the way to and from work follow the same basic patterns as worker
 contacts at work (e.g., we tacitly assume that shared transportation is substantially more likely
 to group together workers who are on the same crew than workers who are on different
 crews).
- 811 812

819

820

821

822

823

824

825

813 Interventions

Apart from the baseline (non-) intervention, we modeled 12 interventions falling into four groups (described in detail in **Text S3C**):

- * "Temperature screening" (1 scenario) denotes temperature screening and isolation where
 all employees arriving for their shift are tested prior to admitting employees to work for
 that shift. The temperature threshold is set at 38°C.
 - "Virus test" (3 scenarios) denotes low-, moderate-, and high-intensity of viral testing and isolation, respectively modeled with the probability p = 5, 30, or 100% of each employee being tested each shift upon arrival at the workplace.
 - "Vaccine" (5 scenarios) denotes primary "vaccination" of unvaccinated workers with 2 doses at a daily probability of p = 2 or 4%; "boosting" of boosting-eligible but unboosted workers at p = 2 or 4% per day; or a combination of both primary and boosting vaccination interventions ("vax+boosting") at p = 2% per day.
- "Physical distancing/Biosafety" (3 scenarios) where physical distancing and/or biosafety • 826 interventions are modeled as generating a 20, 40, or 80% reduction in R_0 at work (i.e., -20, 827 -40 or -80% R_0), such as through the application of masks, face shields, physical barriers, 828 and/or ventilation. The exact approach necessary to achieve these desired effects on R_0 829 will vary across work environments. However, to illustrate how higher-effectiveness 830 interventions may be built by "stacking" multiple lower-effectiveness strategies and to be 831 able to quantify their net cost in the subsequent economic analysis, in absence of required 832 data we assumed: (i) For a low-effectiveness (-20% R_0) intervention, the use of KN95 833 masks, one per employee per shift; (ii) For a moderate-effectiveness (-40% R_0) 834 intervention, a low-effectiveness intervention combined with the use of face shields, one 835 per employee per 30 days; (iii) For a high-effectiveness (-80% R_0) intervention, a 836 moderate-effectiveness intervention combined with ventilation improvement, such as with 837 the use of (a) portable air cleaner(s). 838

We performed counterfactual comparisons of the no-intervention baseline and 12 interventions (**Figure 1A**). To make these comparisons more precise, on a run-by-run basis, we (a) reseed the pseudorandom number generator (pRNG) with the same value before processing each intervention and (b) make use of the pRNG in such a way as to ensure that two runs that start with the same pRNG state and that differ only in the factors that we allow to vary between possible interventions under a given scenario, will have the same pRNG state at all analogous points thereafter.

846

851

852

853

854

858

859

847848 Model running

For each run, the model is first initialized. Then, at each time step, the following processes occur:

- Agents eligible for deisolation (**Text S3C**) are deisolated.
- If any testing is being performed (**Text S3C**), agents who are scheduled to work and (potentially) available are tested.
 - If the testing probability per shift is 1, then all (potentially) available agents are tested.
- 855 o If the testing probability per shift is < 1, then the number of tests to be performed is
 856 determined, and these are performed on the (potentially) available agents in order from
 857 least to most recently tested, randomizing ties.
 - If any agents test positive, they are isolated, and their isolation time is set to the present time.
- Agents to be vaccinated are randomly selected (meaning that they are not infected and either they have just become eligible for a booster and are boosting on time, or they are eligible to receive some form of vaccine, and there is a vaccination-promoting intervention), and their immunity event times, immunity trajectories, and vaccination statuses are updated accordingly.
- Transmission (potentially) occurs, with probabilities as described in **Text S3A**.
- Infected agents who are eligible to leave their current state of infection (i.e., the sum of their time of entering that state and their precalculated duration for that state is less than the time at which the current time step ends) do so, randomly selecting which new infection state to enter, if necessary, as described above.
 - This step is repeated as necessary, i.e., an agent may in principle progress twice in a single time step if the duration of one of their infection states is sufficiently small.
 - If an agent recovers, their last recovery and last immunity event times $(t_{R, i} \text{ and } t_{last, i})$ are set to the present time, and their immunity trajectory is updated.

• Outcomes are recorded for use in subsequent analysis. The ABM model and all analyses were implemented in R software (version 4.0.4) (58).

875 876 877

870

871

872

873

874

878 Model outcomes

Our outcomes of interest can be broadly grouped into those which pertain primarily to public health, and those which pertain primarily to business disruptions and economic impact. We compare these outcomes both across (potential) interventions within a setting scenario and across different scenarios.

883

884 **Public health outcomes**

Our primary public health outcome of interest is the total number of symptomatic SARS-CoV-2 infections that occur across the course of a run. We define this as the number of occasions of an agent transitioning from the IP to IM state between the start of simulation (t = 0) and the end

of simulation (t = T). This includes transitions into IM of agents who were in the E state at 888 889 simulation start, if they transition from E to IP (and, subsequently, to IM) rather than to IA, but does not include the transitions into IM *before* t = 0 for agents that were in IM at simulation start. 890 It also does not include the transitions into IM after t = T of any agents who are in E or IP at 891 simulation end. If the simulation length and transmission dynamics are such as to result in some 892 agents transitioning into IM more than once during the simulation, then we count each such 893 transition separately; hence, it may be possible, depending on user-set parameters, to have a 894 895 number of symptomatic infections that exceeds the number of agents. An additional outcome of interest is the number of total SARS-CoV-2 infections (i.e., including asymptomatic infections) 896 that occur across the course of a run. We present public health outcomes, for each intervention, as 897 898 a curve of the mean over time, as well as violin plots summarizing the cumulative distribution over a defined planning horizon, to allow both comparison of expectations and understanding of 899 the variance. 900

901902 *Economics outcomes*

The main dimensions considered for economic analysis are: (i) direct costs of performing 903 an intervention, and (ii) the productivity costs or benefits of the intervention. To assess (i), we add 904 certain details to our hypothetical interventions, based on how interventions are implemented in 905 real life. Relative to a "no-intervention" baseline of doing nothing, the direct costs of interventions 906 can be expected to always be greater than or equal to zero. Each intervention is compared to the 907 baseline to estimate direct costs of performing each intervention. Calculations of the costs of 908 interventions are described in Text S5. To answer (ii), we estimate the productivity loss based on 909 the worker absences from the infection model with a Cobb-Douglass production model. The 910 Cobb-Douglass production function takes the general form 911

912

916

 $Q = AL^{\beta}K^{\alpha}$

where operations use labor *L* and capital *K* to produce output *Q*, and *A* is some constant. The output elasticities of labor and physical capital are β and α , respectively. In choosing output level *Q*, operations face the following cost function (abstracting from fixed costs):

C = wL + rK

where w is the wage rate and r is the rental rate for capital. Profit-maximizing operations operate at the efficient production frontier in equilibrium.

Based on a previous survey of producers (17), one important assumption made in the 919 model is that the facility can maintain full production (Q_f) with up to 15% of absenteeism without 920 incurring appreciably higher production costs. If a operation can reduce its "full output" labor 921 input allocation L_f to a short-staffed model where $L_s = 0.85L_f$ without reducing full output 922 $(Q_s = Q_f)$ in a costless way, the operation must be able to substitute enough additional capital 923 above the current "full output" allocation in the short run, such that the cost of increased capital is 924 925 completely offset by reduced labor costs. To capture this short-run flexibility, we therefore assume that the current equilibrium is not unique, but instead one in a set of cost-minimizing 926 equilibria where $0.85L_f \leq L \leq L_f$. 927

If labor absenteeism exceeds 15%, however, we assume that the capital allocation now 928 remains fixed at the (higher) 15% absenteeism point, and the production paradigm takes the 929 930 previously described Cobb-Douglass form. Under that framework, since operations cannot substitute capital for labor, they will have to reduce output based on these labor shortages. In an 931 empirical work application of productivity analysis in the food and agricultural sector in the US, 932 933 Ahmad (59) estimates a Bayesian stochastic Cobb-Douglas production function using US statelevel agricultural data from 1960-2004 (n=2,160). He estimates $\alpha = 0.316$ [0.271, 0.362] and $\beta =$ 934 0.437 [0.392, 0.483]. Thus, production is 935

936
$$Q(L) = \begin{cases} Q(L_f) &, & \frac{L}{L_f} \ge 0.85\\ Q(L_f) \left(\frac{L}{0.85L_f}\right)^{0.437} , & \frac{L}{L_f} < 0.85 \end{cases}$$

937

Full production quantity is provided by the users, and estimated production loss is simply 938 $L > 0.0 \Gamma$

1

939
$$Q(L_f) - Q(L) = \begin{cases} 0 & , \quad \overline{L_f} \ge 0.83\\ Q(L_f) \left(1 - \left(\frac{L}{0.85L_f}\right)^{0.437}\right)^{\square}, \quad \frac{L}{L_f} < 0.85\end{cases}$$

940

The results of the above analyses are summarized by the following economic outcomes: the mean 941 number of employees unavailable to work production shifts over time; violin plots summarizing 942 the distribution of the cumulative number of production worker-shifts missed; fraction of shifts 943 short; and total direct expenses, production losses, and total costs associated with an intervention 944 945 (US\$).

Λ

946

947

948 **Scenario analysis**

We tested scenarios corresponding to factors: "setting" ("farm" vs. "facility"), "housing" 949 ("individual" vs. "shared"), "vaccinated" ("high" vs. "none"), and "recovered" ("high" vs. 950 "nothing"). In a full factorial analysis approach, we tested all 16 combinations of these four 951 factors and for each scenario we ran the no-intervention baseline and all 12 interventions. We 952 then constructed regression trees, using the R package rpart (version 4.1.19; using default values 953 for all control parameters) for each of our three primary outcomes (symptomatic infections, 954 worker-shifts unavailable, and total cost) and the two separate contributors to total cost 955 (production losses and intervention expenses) vs. the four scenario parameters and the 5 956 intervention parameters defining our 12 interventions (**Table S13**). In the main text of this paper, 957 we only present a subset of results for which setting is "facility," for reasons discussed in the 958 "Scenario analysis" subsection of the Results section. 959

960 961

962 Sensitivity analysis

We evaluated the parameter sensitivity for four outcomes using the OFAT approach. Three 963 outcomes were the total symptomatic infections, total number of worker-shifts missed and total 964 cost over the simulation length. The fourth outcome was the effective reproduction number ($R_{eff.}$) 965 at the start of simulation. Because of the large number of parameters to be examined, under 966 (initially) a variety of scenarios, we averaged results over batches of 100 runs each, rather than 967 the 1000 runs that we use in most other contexts. In general, for a given parameter whose value in 968 our model was x, we examined results when that parameter was set to 1/2 x, x, and 2x (Table 969 970 **S14**). For 2 parameters ($T_{V2 \rightarrow B}$ and $T_{1st V2 \rightarrow 0}$), one of these values was impossible, given a requirement that it be possible for some individuals to be eligible for boosting at simulation start. 971 For these parameters, we set the relevant value to the most extreme possible value in the same 972 direction (i.e., 212.5 days for (increased) $T_{V2\rightarrow B}$ and 305 days for (reduced) $T_{1st V2 \rightarrow 0}$). 973

In order to estimate R_{eff} at the start of simulation (other outcomes were measured without 974 this modification), we modified the model so that, when an employee was infected, instead of 975 their infection status being changed from Not Infected to Exposed, their immunity was set to 976 Recovered, and their $t_{\text{last, i}}$ was reset to the current time. Conceptually, this amounts to their 977 "skipping over" any infected states, and going directly from infection to recovery. This ensured 978 that all employee-to-employee transmissions would necessarily be from employees who were 979

infected at the start of simulation. We then ran the model starting with a single Exposed employee (as is the default), and observed the number of employee-to-employee transmissions that occurred. The average of that number across multiple runs was then used as an empirical estimate of R_{eff} . In scenarios with "individual" housing, the community-acquired infection was allowed to occur (likewise transferring infected employees directly into a Recovered state, meaning that they were not immediately infectible by the index case), but was not included in the count of employee-to-employee transmissions measured by R_{eff} .

987 We initially examined the results of sensitivity analysis, using default user-settable parameters, except as noted, across the same range of settings as we initially considered for 988 scenario analysis. We found that, for most parameters, sensitivity was higher in "high" settings 989 (i.e., with a history of both vaccination and recovery from natural infection) than in historical or 990 pseudo-historical settings, higher in facility settings than in farm settings, and higher in settings 991 with shared housing than in settings with individual housing. For this reason, we focused our 992 further examination on a setting of a facility, with all parameters default except for housing, 993 which was "shared" instead of "individual" (with physical distancing in shared housing at the 994 default level). Looking back at scenario analysis, this is equivalent to the scenario in which both 995 "vaccination" and "recovered" were "high." 996

For each parameter-intervention-outcome combination, we obtained three mean outcome 997 values, as described above. We divided the largest of those three values by the smallest to obtain a 998 simple measure ω of the sensitivity that could address both monotonic and non-monotonic effects. 999 For each parameter, we then chose the largest such measure (ω_{max}) across all intervention-1000 outcome combinations. We then selected for depiction and discussion in the Results section those 1001 parameters for which $\omega_{max} \ge 2$ (all results are shown in **Figures S5-S8**). As the only exception to 1002 this process, we omitted the baseline no-intervention scenario in the Total Cost outcome, as the 1003 sensitivity measure for this outcome-intervention was generally undefined or (rarely, and 1004 seemingly at random) infinite, due to the extreme rarity of non-zero Total Cost at baseline. 1005 1006

1007 1008 **References**

- J. Luckstead. R. M. Nayga Jr., H. A. Snell, Labor issues in the food supply chain amid the COVID-19 pandemic. *Appl. Econ. Perspect. Policy.* 43, 382-400 (2021).
- National Conference of State Legislatures, (NCSL), "COVID-19: Essential workers in the
 States" (2021, www.ncsl.org/labor-and-employment/covid-19-essential-workers-in-the states#Map).
- 1014 3. D. Laborde, W. Martin, J. Swinnen, R. Vos, COVID-19 risks to global food security. *Science* 1015 369, 500-502 (2020).
- 4. J. N. Marchant-Forde, L. A. Boyle, COVID-19 effects on livestock production: A one welfare
 issue. *Front. Vet. Sci.* 7, 585787 (2020).
- D. Peel, Beef supply chains and the impact of the COVID-19 pandemic in the United States,
 Anim. Front. 11, 33–38 (2021).
- 1020 6. US Department of Agriculture, Economic Research Service, (USDA ERS). 2023. "Farm
 1021 Sector Income During the Pandemic" November 30, 2023. https://www.ers.usda.gov/covid 1022 19/farms-and-farm-households/#income.
- 1023 7. A. Weersink A, M. von Massow, N. Bannon, J. Ifft, J. Maples, K. McEwan, M. G. S.
- 1024 McKendree, C. Nicholson, A. Novakovic, A. Rangarajan, T. Richards, B. Rickard, J. Rude,
- 1025 M. Schipanski, G. Schnitkey, L. Schulz, D. Schuurman, K. Schwartzkopf-Genswein, M.
- 1026 Stephenson, J. Thompson, K. Wood, COVID-19 and the agri-food system in the United States
- 1027 and Canada. *Agric. Syst.* **188**, 103039 (2021).

- 8. L. Douglas. 2021. "Mapping Covid-19 Outbreaks in the food system." Food & Environment Reporting Network, July 26, 2023. https://thefern.org/2020/04/mapping-covid-19-in-meatand-food-processing-plants/.
- M. A. Waltenburg, C. E. Rose, T. Victoroff, M. Butterfield, J. A. Dillaha, A. Heinzerling, M.
 Chuey, M. Fierro, R. H. Jervis, K. M. Fedak, A. Leapley, J. A. Gabel, A. Feldpausch, E. M.
- 1033 Dunne, C. Austin, C. S. Pedati, F. S. Ahmed, S. Tubach, C. Rhea, J. Tonzel, A. Krueger, D.
- 1034 A. Crum, J. Vostok, M. J. Moore, H. Kempher, J. Scheftel, G. Turabelidze, D. Stover, M.
- 1035 Donahue, D. Thomas, K. Edge, B. Gutierrez, E. Berl, M. McLafferty, K. E. Kline, N. Martz,
- J. C. Rajotte, E. Julian, A. Diedhiou, R. Radcliffe, J. L. Clayton, D. Ortbahn, J. Cummins, B.
- Barbeau, S. Carpenter, J. C. Pringle, J. Murphy, B. Darby, N. R. Graff, T. K. H. Dostal, I. W.
- Pray, C. Tillman, D. A. Rose, M. A. Honein, Coronavirus disease among workers in food
 processing, food manufacturing, and agriculture workplaces. *Emerg. Infect. Dis.* 27, 243-249
 (2021).
- 1041 10. C. A. Taylor, C. Boulos, D, Almond, livestock plants and COVID-19 transmission. *PNAS* 1042 117, 31706-31715 (2020).
- 1043 11. T. L. Saitone, K. Aleks Schaefer, D. P. Scheitrum, COVID-19 morbidity and mortality in U.S.
 1044 meatpacking counties. *Food Policy*. 101, 102072 (2021).
- 1045 12. Z. Chen, E. Bulut, A. Trmčić, R. Ivanek, Rapid review of government issued documents
 relevant to mitigation of COVID-19 in the U.S. food manufacturing and processing industry.
 1047 Food Prot. Trends. 42, 426–438 (2022).
- 1048 13. A. Trmčić, E. Demmings, K. Kniel, M. Wiedmann, S. Alcaine, Food safety and employee
 1049 health implications of COVID-19: A review. *J. Food. Prot.* 84, 1973-1989 (2021).
- 14. D. J. Hayes, L. L. Schulz, C. E. Hart, K. L. Jacobs, A descriptive analysis of the COVID-19
 impacts on U.S. pork, turkey, and egg markets. *Agribusiness (N Y N Y)* 37, 122-141 (2021).
- 1052 15. P. K. Henneberger, J. M. Cox-Ganser, G. M. Guthrie, C. P. Groth, Estimates of COVID-19
 vaccine uptake in major occupational groups and detailed occupational categories in the
 United States, April-May 2021. *Am. J. Ind. Med.* 65, 525-536 (2022).
- 1055 16. I. T. Agaku, C. Adeoye, T. G. Long, Geographic, Occupational, and sociodemographic
 1056 variations in uptake of COVID-19 booster doses among fully vaccinated US adults, December
 1057 1, 2021, to January 10, 2022. *JAMA Netw Open.* 5, e2227680 (2022).
- 1058 17. S. Llanos-Soto, E. Bulut, S. I. Murphy, C. J. Henry, C. Zoellner, M. Wiedmann, D.
 1059 Wetherington, A. Adalja, S. D. Alcaine, R. Ivanek, Survey of implemented mitigation
 1060 strategies and further needs of the U.S. food industry to control COVID-19 in the work
 1061 environment in early 2021. *Food Prot. Trends.* 43, 40-60 (2023).
- 1062 18. S. Vecherin, D. Chang, E. Wells, B. Trump, A. Meyer, J. Desmond, K. Dunn, M. Kitsak, I.
 1063 Linkov, Assessment of the COVID-19 infection risk at a workplace through stochastic
 1064 microexposure modeling. *J. Expo. Sci. Environ. Epidemiol.* **32**, 712-719 (2022).
- 1065 19. P. C. L. Silva, P. V. C. Batista, H. S. Lima, M. A. Alves, F. G. Guimarães, R. C. P. Silva,
 1066 COVID-ABS: An agent-based model of COVID-19 epidemic to simulate health and
 1067 economic effects of social distancing interventions. *Chaos. Solitons Fractals* 139, 110088
 1068 (2020).
- 20. E. Cuevas, An agent-based model to evaluate the COVID-19 transmission risks in facilities.
 Comput. Biol. Med. 121, 103827 (2020).
- 1071 21. N. M. Ferguson, D. Laydon, G. Nedjati-Gilani, N. Imai, K. Ainslie, M. Baguelin, S. Bhatia,
 1072 A. Boonyasiri, Z. Cucunubá, G. Cuomo-Dannenburg, A. Dighe, I. Dorigatti, H. Fu, K.
- 1073 Gaythorpe, W. Green, A. Hamlet, W. Hinsley, L. C Okell, S. van Elsland, H. Thompson, R.
- 1074 Verity, E. Volz, H. Wang, Y. Wang, P. G. T. Walker, C. Walters, P. Winskill, C. Whittaker,
- 1075 C. A Donnelly, S. Riley, A. C. Ghani, "Report 9 Impact of non-pharmaceutical interventions
- 1076 (NPIs) to reduce COVID-19 mortality and healthcare demand" (WHO Collaborating Centre
- 1077 for Infectious Disease Modelling; MRC Centre for Global Infectious Disease Analysis; Abdul

1078		Latif Jameel Institute for Disease and Emergency Analytics; Imperial College London, 2020;
1079		www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-9-impact-of-npis-
1080		on-covid-19/).
1081	22.	M. D'Orazio, G. Bernardini, E. Quagliarini, A probabilistic model to evaluate the
1082		effectiveness of main solutions to COVID-19 spreading in university buildings according to
1083		proximity and time-based consolidated criteria. Build. Simul. 14, 1795–1809 (2021).
1084	23.	E. Okafor, B. Bass, "Modelling the spread of Covid-19 in a typical oil and gas facility setting"
1085		(SPE Nigeria Annual International Conference and Exhibition, 2021).
1086	24.	H. Inoue, Y. Todo, The propagation of economic impacts through supply chains: The case of
1087		a mega-city lockdown to prevent the spread of COVID-19. <i>PLoS One</i> 15 , e0239251 (2020).
1088	25.	F. Dignum, V. Dignum, P. Davidsson, A. Ghorbani, M. van der Hurk, M. Jensen, C.
1089		Kammler, F. Lorig, L. G. Ludescher, A. Melchior, R. Mellema, C. Pastrav, L. Vanhee, H.
1090		Verhagen, Analysing the combined health, social and economic impacts of the corovanvirus
1091		pandemic using agent-based social simulation. Minds Mach. (Dordr). 30, 177-194 (2020).
1092	26.	S. L. Chang, N. Harding, C. Zachreson, O. M. Cliff, M. Prokopenko, Modelling transmission
1093		and control of the COVID-19 pandemic in Australia. Nat. Commun. 11, 5710 (2020).
1094	27.	J. Dehning, J. Zierenberg, F. P. Spitzner, M. Wibral, J. P. Neto, M. Wilczek, V. Priesemann,
1095		Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions.
1096		<i>Science</i> 369 , eabb9789 (2020).
1097	28.	A. R. Tuite, D. N. Fisman, A. L. Greer, Mathematical modelling of COVID-19 transmission
1098	•	and mitigation strategies in the population of Ontario, Canada. CMAJ 192, E497-E505 (2020).
1099	29.	J. Lou, S. Borjigin, C. Tang, Y. Saadat, M. Hu, D. A. Niemeier, Facility design and worker
1100	20	justice: COVID-19 transmission in meatpacking plants, Am. J. Ind. Med. 66, 713-727 (2023).
1101	30.	M. Pangallo, A. Aleta, R. M. del Rio-Chanona, A. Pichler, D. Martin-Corral, M. Chinazzi, F.
1102		Lafond, M. Ajelli, E. Moro, Y. Moreno, A. Vespignani, J. D. Farmer, The unequal effects of
1103		the health–economy trade-off during the $COVID-19$ pandemic, <i>Ivat. Hum. Benav.</i> 5 , 204–275 (2024)
1104	21	(2024). 7 Du A Danday V Bai M C Eitznatriak M Chinazzi A Dastara y Diantti M Lashmann
1105	51.	Z. Du, A. Paluey, T. Bal, M. C. Fitzpatrick, M. Chinazzi, A. Pastore y Flontu, M. Lachmann, A. Vasnignani, P. I. Cowling, A. P. Calvani, L. A. Mayora, Comparative cost offectiveness of
1100		SARS-CoV-2 testing strategies in the USA: A modelling study Lancet Public Health 6 e184-
1107		e191 (2021)
1100	32	The U.S. Census Bureau 2022 "United States" March 21, 2022
1110	52.	https://data.census.gov/cedsci/profile?a=United%20States&g=0100000US
1110	33	Centers for Disease Control and Prevention (CDC) 2022 "COVID-19 vaccination
1112	55.	demographics in the United States. National" May 16, 2022.
1112		https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-Demographics-in-the-United-
1114		St/km4m-vcsb/about data.
1115	34.	Centers for Disease Control and Prevention. (CDC). 2022. "COVID data tracker." February
1116		21, 2022. https://covid.cdc.gov/covid-data-tracker
1117	35.	Centers for Disease Control and Prevention, (CDC). 2022. "Estimated COVID-19 burden"
1118		February 19, 2022. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html.
1119	36.	T. Günther, M. Czech-Sioli, D. Indenbirken, A. Robitaille, P. Tenhaken, M. Exner, M.
1120		Ottinger, N. Fischer, A. Grundhoff, M. M. Brinkmann, SARS-CoV-2 outbreak investigation
1121		in a German meat processing plant. EMBO Mol. Med. 12, e13296 (2020).
1122	37.	J. Steinberg, E. D. Kennedy, C. Basler, M. P. Grant, J. R. Jacobs, D. Ortbahn, J. Osburn, S.
1123		Saydah, S. Tomasi, J. L. Clayton, COVID-19 outbreak among employees at a meat processing
1124		facility — South Dakota, March–April 2020. CDC MMWR 69, 1015-1019 (2020).
1125	38.	J. T. Nardini, R. E. Baker, M. J. Simpson, K. B. Flores, Learning differential equation models
1126		from stochastic agent-based model simulations. J. R. Soc. Interface 18 20200987 (2021).

- 39. O. Mancur, *The Logic of Collective Action: Public Goods and the Theory of Groups* (Harvard University Press, Cambridge, MA, 1971).
- 40. L. Kalunga, E. Bulut, Z. Chen, Y. Li, R. Ivanek, Increasing vaccine uptake among employees
 within the non-health related critical infrastructure sectors: A review. *Hum. Vaccin. Immunother.* 19, 2135852 (2023).
- 1132 41. Tyson Foods, "Tyson Foods to require Covid-19 vaccinations for its U.S. workforce." (2021;
- 1133 www.tysonfoods.com/news/news-releases/2021/8/tyson-foods-require-covid-19-vaccinations 1134 its-us-workforce).
- 42. L. Zumbach, 2021. "McDonald's will require U.S. office employees get the COVID-19
 vaccine." Chicago Tribune, August 11, 2021 at 5:42 pm.
- https://www.chicagotribune.com/business/ct-biz-mcdonalds-mandate-covid-19-vaccine 20210811-iyy6jale2ng2dgenlz7ig3na6m-story.html.
- 43. D. McMillon. 2021. "Walmart announces COVID-19 vaccination policy for campus officeassociates." Walmart, July 30, 2021.
- https://corporate.walmart.com/newsroom/2021/07/30/walmart-announces-covid-19 vaccination-policy-for-campus-office-associates.
- 44. T. Polansek. 2022. "Tyson Foods ends COVID-19 vaccine mandate for employees." Reuters,
 November 16, 2022 at 6:04 pm. https://www.reuters.com/business/healthcare-
- 1145 pharmaceuticals/tyson-foods-ends-covid-19-vaccine-mandate-employees-2022-11-16/.
- 45. M. Barnes, P. E. Sax, Challenges of "Return to Work" in an ongoing pandemic. *N. Engl. J. Med.* 383, 779-786 (2020).
- 46. P. L. Sacco, F. Valle, M. De Domenico, Proactive vs. reactive country responses to the
 COVID-19 pandemic shock. *PLOS Glob. Public Health.* 3, e0001345 (2023).
- 47. E. K. Accorsi, J. Samples, L. A. McCauley, N. Shadbeh, Sleeping within six feet: challenging
 Oregon's labor housing COVID-19 guidelines. *J. Agromedicine*. 25, 413-416 (2020).
- 48. E. Haley, S. Caxaj, G. George, J. Hennebry, E. Martell, J. McLaughlin, Migrant farmworkers
 face heightened vulnerabilities during COVID-19. *JAFSCD*. 9, 35-39 (2020).
- 49. FInd CoV Control. January 1, 2024. https://www.foodcovidcontrol.com/FOODCTL/index.jsp.
- 1155 50. National Center for Farmworker Health, "Agricultural Worker Demographics" (NCFH,
- Health Resources and Services Administration (HRSA) of the U.S. Department of Health and
 Human Services (HHS), 2018; www.ncfh.org/agricultural-worker-demographics.html).
- 51. S. M. Moghadas, M. C. Fitzpatrick, P. Sah, A. Pandey, A. Shoukat, B. H. Singer, A. P.
 Galvani, The implications of silent transmission for the control of COVID-19 outbreaks. *Proc. Natl. Acad. Sci.* 117, 17513–17515 (2020).
- 52. U.K. Health Security Agency, "COVID-19 vaccine surveillance report week 4" (UKHSA Gateway Number GOV-11226, UK Health Security Agency, 2022;
- 1163https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/1164file/1050721/Vaccine-surveillance-report-week-4.pdf).
- 53. N. Bobrovitz, H. Ware, X. Ma, Z. Li, R. Hosseini, C. Cao, A. Selemon, M. Whelan, Z. Premji,
 H. Issa, B. Cheng, L. J. Abu Raddad, D. L. Buckeridge, M. D. Van Kerkhove, V. Piechotta,
- 1167 M. M. Higdon, A. Wilder-Smith, I. Bergeri, D. R. Feikin, R. K. Arora, M. K. Patel, L. Subissi,
- 1168 Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the
- omicron variant and severe disease: A systematic review and meta-regression. *Lancet Infect. Dis.* 23, 556–567 (2023).
- 1171 54. Pfizer, "Vaccine information fact sheet for recipients and caregivers about Comirnaty
- 1172 (COVID-19 vaccine, mRNA), the Pfizer-Biontech COVID-19 vaccine, and the Pfizer-
- Biontech COVID-19 vaccine, bivalent (original and omicron BA.4/BA.5) to prevent
- 1174 coronavirus disease 2019 (COVID-19) for individuals 12 years of age and older" (2022;
- 1175 https://labeling.pfizer.com/ShowLabeling.aspx?id=14472&format=pdf).

55. C. C. Kerr, R. M. Stuart, D. Mistry, R. G. Abeysuriya, K. Rosenfeld, G. R. Hart, R. C. Núñez, 1176 J. A. Cohen, P. Selvaraj, B. Hagedorn, L. George, M. Jastrzębski, A. S. Izzo, G. Fowler, A. 1177 Palmer, D. Delport, N. Scott, S. L. Kelly, C. S. Bennette, B. G. Wagner, S. T. Chang, A. P. 1178 Oron, E. A. Wenger, J. Panovska-Griffiths, M. Famulare, D. J. Klein, Covasim: An agent-1179 based model of COVID-19 dynamics and interventions. PLoS Comput. Biol. 17, e1009149 1180 (2021). 1181 56. M. Arabi, Y. Al-Najjar, N. Mhaimeed, M. A. Salameh, P. Paul, J. AlAnni, A. A. Abdelati, I. 1182 1183 Laswi, B. Khanjar, D. Al-Ali, A. Elshafeey, O. Mhaimeed, Z. Burney, A. D'Souza, P. Sinha, M. Bhatti, K. V. Pillai, M. Homssi, K. Bshesh, L. Yagan, D. Zakaria, Severity of the Omicron 1184 SARS-CoV-2 variant compared with the previous lineages: A systematic review. J. Cell Mol. 1185 Med. 27, 1443–1464 (2023). 1186 57. M. Bielecki, G. A. G. Crameri, P. Schlagenhauf, T. W. Buehrer, J. W. Deuel, Body 1187 temperature screening to identify SARS-CoV-2 infected young adult travellers is ineffective. 1188 Travel Medicine and Infectious Disease 37, 101832 (2020). 1189 58. G. A. Okove, H. I. Kamara, M. Strobeck, T. A. Mellman, J. Kwagyan, A. Sullivan, A. S. 1190 Byrd, B. Shokrani, H. E. Mighty, Diagnostic accuracy of a rapid diagnostic test for the early 1191 detection of COVID-19. Journal of Clinical Virology 147, 105023 (2022). 1192 59. S. Ahmad, Economic theory, applications and issues - estimating input-mix efficiency in a 1193 parametric framework: application to state-level agricultural data for the United States. ISSN: 1194 1444-8890 (2017). 1195 60. Center for Disease Prevention, (CDC), "Ending isolation and precautions for people with 1196 COVID-19: interim guidance" (2022; www.cdc.gov/coronavirus/2019-ncov/hcp/duration-1197 isolation.html) 1198 61. Pete's Air Purifiers. "Oransi EJ120 HEPA air purifier with carbon filter, white/black", 1199 January 3, 2024. https://petesairpurifiers.com/products/oransi-ej120-hepa-air-purifier-with-1200 carbon-filter-white-black 1201 62. Airpura. "P600 - germs, mold and chemicals reduction air purifier", January 3, 2024. 1202 https://www.airpura.com/products/p600-germs-mold-and-chemicals-reduction 1203 63. EnviroKlenz. "EnviroKlenz Air System Plus", January 3, 2024. 1204 1205 https://enviroklenz.com/product/enviroklenz-mobile-uvmodel/?gc id=1121169327&h ad id=572045475019&gclid=Cj0KCQiAoY-1206 PBhCNARIsABcz770NANY4f3xtgX2LdAkMTMBH4SrBywLkVJux8FdafgyOeDO8uqdt75 1207 AaAgwpEALw wcB 1208 64. Aeris. "Medical PRO Air Purifier", January 3, 2024. https://www.amazon.com/aeris-aair-1209 Medical-Purifier-Hospital-Grade/dp/B08OW78W7C?th=1 1210 65. BladeAir. "Blade Air HEPA Air Purifier", January 3, 2024. https://bladeair.com/iaq-1211 solutions/hepa/ 1212 66. K. VanderWaal, L. Black, J. Hodge, A. Bedada, S. Dee, Modeling transmission dynamics and 1213 effectiveness of worker screening programs for SARS-CoV-2 in pork processing plants. PLoS 1214 One 16. e0249143 (2021). 1215 67. M. O'Driscoll, G. Ribeiro Dos Santos, L. Wang, D. A. T. Cummings, A. S. Azman, J. 1216 Paireau, A. Fontanet, S. Cauchemez, H. Salje, Age-specific mortality and immunity patterns 1217 of SARS-CoV-2. Nature 590, 140-145 (2021). 1218 68. R. Verity, L. C. Okell, I. Dorigatti, P. Winskill, C. Whittaker, N. Imai, G. Cuomo-1219 Dannenburg, H. Thompson, P. G. T. Walker, H. Fu, A. Dighe, J. T. Griffin, M. Baguelin, S. 1220 Bhatia, A. Boonyasiri, A. Cori, Z. Cucunubá, R. FitzJohn, K. Gaythorpe, W. Green, A. 1221 Hamlet, W. Hinsley, D. Laydon, G. Nedjati-Gilani, S. Riley, S. van Elsland, E. Volz, H. 1222 Wang, Y. Wang, X. Xi, C. A. Donnelly, A. C. Ghani, N. M. Ferguson, Estimates of the 1223 1224 severity of coronavirus disease 2019: a model-based analysis. Lancet Infect. Dis. 20, 669-677 (2020).1225

- 1226
- 1227

1228 Acknowledgments

1229 The authors thank the Industry Advisory Council, which was assembled to guide modeling work

- and comprised of executive-level leaders in the major US produce farms and food processing
- companies and an official in the Centers for Disease Control and Prevention, for valuable
- 1232 feedback on the structure of FInd CoV Control. The authors also thank Ms. Yu Tang (Dyson
- 1233 School of Applied Economics and Management, Cornell SC Johnson College of Business,
- 1234 Cornell University, Ithaca, NY, USA) for her contribution to the methodology, investigation and
- 1235 writing of the original draft for the evaluation of economic impacts of interventions.
- 1236
- 1237 Funding:
- 1238 Agriculture and Food Research Initiative from the USDA National Institute of Food and
- 1239 Agriculture, Competitive Grant no. 2020-68006-32875 (RI, AA, SA, MW).
- 1240 Cornell Institute for Digital Agriculture (CIDA) (RI, MW)
- 1241 Artificial Intelligence Institute for Next Generation Food Systems from the USDA National
- 1242 Institute of Food and Agriculture, grant 2020-67021-32855 (RI, MW)
- 1243 The funders had no role in the study design, data collection, and analysis, decision to publish, or
- 1244 preparation of the manuscript.

1246 Author contributions:

- 1247 Conceptualization: CH, RI, AA
- 1248 Methodology: CH, RI, AA, CZ, DW
- 1249 Investigation: CH, RI, EB, SIM
- 1250 Visualization: CH, RI
- 1251 Supervision: RI, AA
- 1252 Writing—original draft: CH, RI
- 1253 Writing—review & editing: CH, EB, SIM, CZ, AA, DW, MW, SA, RI
- 1254

1245

1255 **Competing interests:**

- 1256 CZ is employed at iFoodDecisionSciences, Inc., which hosted the web-interface developed as an
- extension of a previous version of FInd CoV Control described here (49) until December 2023;
- this interface is currently hosted by iDecisionSciences, LLC. FInd CoV Control was licensed to
- 1259 iDecisionSciences, Inc. under the GNU General Public License. DW is the founder of
- iFoodDecisionSciences, Inc and iDecisionSciences, LLC. All other authors declare they have nocompeting interests.
- 1262

1263 **Data and materials availability:**

- All data are available in the main text or the supplementary materials. R code is available under
 GPL-2.0 license at <u>https://github.com/IvanekLab/covid-journal-code</u>
- 1266

1267 **Figures and Tables**

1268

A. Modules of the FInd CoV Control Tool

Disease transmission

Individual agents transition through COVID-19 infection states (panel B.iv) under each of the following scenarios:

1 baseline (no-intervention) scenario

12 intervention scenarios:

- Temperature screening & Isolation (1 scenario)
- Viral testing & Isolation (3 scenarios)
- Vaccination (primary & boosting) (5 scenarios)
- Physical distancing / biosafety (3 scenarios)



Public health outcomes:

- Number of employees with symptomatic infection
- Number of employees with asymptomatic infection

Economic outcomes:

- Number of employees unavailable to work
- The fraction of shifts with employee shortage
- Total direct expenses (\$)
 - production losses
 - total costs associated with an intervention

1269 1270

Figure 1. Overview of the FInd CoV Control tool. (A) Three modules of the tool: Employee
 population, Work environment and Disease transmission. (B) Module building blocks: B.i
 Example of a shift schedule, B.ii Agent hierarchy in a food processing facility, B.iii
 Heatmap showing a contact network among agents in a food processing facility and
 relative rates of contacts, and B.iv Infection states in the COVID-19 disease transmission
 module. (C) List of outcomes recorded for each iteration of a simulation with the FInd
 CoV Control Tool.

B. Building blocks





Figure 2. Illustration of public health outcomes for baseline (no intervention) and each of 1279 1280 the interventions in absolute terms as well as relative to the baseline. Results for number of symptomatic infections in a processing facility with 103 employees over the 90 1281 days of the simulation run are shown (results for total infections are similar, apart from 1282 scale). (A and B) The mean across all runs of the incidence (A) and prevalence (B) of 1283 symptomatic infection, at each time point; these illustrate the dynamics over time, but also 1284 conceal the high level of variation between runs. (C) The fraction of runs for which the 1285 1286 total number of symptomatic infections is greater than zero. (D) Violin plots representing the distribution, between runs, of the *total* number of symptomatic infections; these violin 1287 plots illustrate the bimodal nature of most distributions. (E) Violin plots representing the 1288 distribution of *counterfactual effects* of the various interventions, i.e., the distribution of 1289 pairwise differences between corresponding runs with and without that intervention (the 1290 number at that intervention, N_I , minus the number at baseline, N_B ; $N_I - N_B$), for runs that 1291 do have one or more symptomatic infections at baseline. (F) Violin plots representing the 1292 distribution of pairwise *fractional* differences (i.e., $(N_I - N_B)/N_B$), for runs with a non-1293 zero number of symptomatic infections at baseline. For three of the interventions, there is 1294 a single positive outlier (i.e., 1 iteration out of 1,000 runs per intervention) that is cut off 1295 by the axis limits to avoid excessively compressing the depiction of the other 11,997 1296 points. 1297

1298



- Figure 3. Illustration of unavailability for baseline (no intervention) and each of the 1300 interventions in absolute terms as well as relative to the baseline. Unavailability (i.e., 1301 worker-shifts missed) depends not only on how many employees are infected, and how 1302 many of those are symptomatic, but also on how likely an infected employee (whether 1303 symptomatic or asymptomatic) is to be removed from the workforce (due to 1304 hospitalization, or to detection and isolation). All results are for 90-day long simulation 1305 runs. (A) The mean across all runs of the number of employees unavailable to work their 1306 1307 scheduled production shift, for each day of the simulation; this illustrates the dynamics over time, but also conceals the substantial level of variation between runs. (B) Violin 1308 plots representing the distribution, between runs, of the sum of the number of workers 1309 unavailable to work their scheduled production shift, over all such shifts: this violin plot 1310 illustrates the varying shapes of these distributions. (C) The fraction of runs for which the 1311 total number of worker-shifts missed is greater than zero. (D and E) Violin plots 1312 representing the distribution of *counterfactual effects* of the various interventions, i.e., the 1313 distribution of *pairwise differences* between *corresponding* runs with and without that 1314 intervention (the number at that intervention, N_I , minus the number at baseline, N_B ; N_I – 1315 N_{P} , for runs with zero (panel D) and non-zero (panel E) worker-shifts missed at baseline. 1316 (F) Violin plots representing the distribution of pairwise *fractional* differences (i.e., $(N_I -$ 1317 N_B / N_B), for runs with non-zero worker-shifts missed at baseline. 1318 1319 1320
- 1320



1322

Figure 4. Illustration of costs for baseline (no intervention) and each of the interventions. All 1323 1324 panels consist of violin plots (although in some cases, these may be sufficiently horizontally compressed that this is not obvious) representing the distribution (across runs 1325 within an intervention) of an outcome. All results are for 90-day long simulation runs. (A) 1326 Distribution of direct intervention expenses (supplies purchased and/or additional wages 1327 paid for tasks performed outside of an individual's normal scheduled working hours); 1328 these are generally relatively constant for an intervention, and are always US\$0 by 1329 definition for the baseline. (B) Distribution of production losses due to worker absences; 1330 as a result of unavailability (occurring only on days when >15% of workers miss their 1331 shift) this is almost always US\$0 in the absence of a testing intervention. Here, we can see 1332 that low to moderate levels of routine viral testing may be insufficient to interrupt 1333 transmission, but sufficient to remove significant numbers of employees through detection 1334 and isolation, and thus causing significant production losses. (C) Distribution of total costs 1335 (in US\$), which we define to be the sum of intervention expenses and production losses. 1336 (D) Fraction of production shifts (within a single run) that are "short", i.e., more than 15% 1337 of workers absent ("0%" means that in a particular run none of the shifts were "short"). 1338



- 1339 1340
- 1341
- 1342 1343
- 1344
- 1345
- 1346 1347

1348

represent values of the parameter listed in the node itself. Where there are only two values for a parameter, the value is sometimes only listed explicitly on the left branch, to save space; the right branch simply has the value of that parameter that the left branch does not. In all cases, branches are ordered by making the left branch the one with the *lower* average value for the outcome represented in that panel. (This does not, however, result in *all* leaves being ordered from lowest to highest, because the branches are not allowed to cross.) The value at each leaf indicates the mean value of the outcome across relevant scenarios x interventions x runs over the 90 days of the simulation run, and *n* indicates the

- number of runs represented by the leaf (out of 104,000 runs). (A) Total number
- 1350 (Cumulative Incidence) of Symptomatic Infections, (B) Total number of Worker-Shifts
- 1351 Unavailable, (C) Cumulative intervention expenses (in US\$), (D) Cumulative production
- 1352 losses (in US\$).
- 1353



1354 Figure 6. Dependence of the mean value of four major outcomes (columns), summed over 1355 the course of a 90-day simulation, on 5 selected non–user-settable parameters (rows), 1356 and on select interventions (colors). The outcomes, columns from left to right, are total 1357 number of symptomatic infections, total number of production worker-shifts missed, 1358 effective reproduction number, and total cost in US\$. The parameters examined, rows top 1359 to bottom, are ψ ("SEVERE MULTIPLIER" denoting a parameter scaling the fraction of 1360 symptomatic infections that become severe); μ_{IM} , and μ_{IS} (mean duration of mild 1361 ("duration IM mean") and severe ("duration IS mean") infection, respectively); β_{IM} 1362

1363	("p_trans_IM" denoting relative probability of transmission, per potentially infectious
1364	contact, during mild infection); and φ ("fraction_ssp_symptomatic" denoting a parameter
1365	that pertains to how much protection from developing symptomatic disease Recovered and
1366	Hybrid immunity provide to infected individuals). The interventions examined were
1367	Baseline (black), Temperature Screening (dark blue), Virus Test at $p = 0.3$ / working day
1368	(red), Physical distancing/Biosafety at -40% R ₀ (dark green), and Vax + Boosting at $p =$
1369	0.02/day (yellow). These colors are the same as those in Figures 2, 3, and 4, although the
1370	line type may vary. The x-axis of each plot represents the <i>multiplier</i> applied to the
1371	parameter in question (i.e., 0.5, 1, or 1.5 for all of the parameters depicted here).
1372	

1373 **Table 1. Summary of agent attributes.** *'Ramp-up' refers to an initial increase in immunity

following a vaccination event. Additional information for $P_{\text{last, IP, i}}$ and $P_{\text{last, IS, i}}$ is in **Table S2**.

1375 Distributions for infection stage durations are in **Table 4**. **Table S12** is a version of this table with

additional notes and information on how attributes are set at simulation start and/or during the

1377 simulation.

Symbol	Description	Directly affect(s)
Ai	Age	Transition probabilities (see Table S1)
<i>p</i> stage, i	Transition probabilities at full susceptibility	Asymptomatic vs. Symptomatic infection; recovery from each stage on the symptomatic path vs. further progression/ death
D _{stage} i	Infection stage durations	Timing of recovery/ progression/ death
$t_{\text{event_type, i}}$ ($t_{V1, i}, t_{V2, i}$, $t_{B, i}$, and $t_{R, i}$)	Immunity event times	Protection against Any Infection ($P_{E, i}$) and either overall Protection against Symptomatic Infection ($P_{IP, i}$) or overall Protection against Severe Infection ($P_{IS, i}$)
$\begin{array}{l} t_{infection \ status, \ i} \\ (t_{E, \ i}, \ t_{IA, \ i}, \ t_{IP, \ i}, \\ t_{IM, \ i}, \ t_{IS, \ i}, \ and \\ t_{IC, \ i}) \end{array}$	Infection and infection progression times	Timing of recovery/ progression/ death
Ci	Immunity trajectories	Protection against Any Infection ($P_{E, i}$) and either overall Protection against Symptomatic Infection ($P_{IP, i}$) or overall Protection against Severe Infection ($P_{IS, i}$)
t _{last, i}	Time of last immunity event	Immunity components (for certain immunity trajectories)
P _{last, E, i}	"Previous" (at the time of the last immunity event) level of Protection against Any Infection ($P_{E, i}$)	Current level of Protection against Any Infection, during ramp-up phases only
P _{last, IP, i}	"Previous" (at the time of the last immunity event) level of overall Protection against Symptomatic Infection (<i>P</i> _{IP, i})	Current overall Protection against Symptomatic Infection, during ramp-up phases only
P _{last, IS, i}	"Previous" (at the time of the last immunity event) level of overall Protection against Severe Infection (<i>P</i> _{IS, i})	Current overall Protection against Severe Infection, during ramp-up phases only
<i>Р</i> _{Е, і}	Protection against Any Infection	Relative susceptibility to infection (i.e., to transitioning from Not Infected to Exposed)
P _{IP E, i}	Protection against Symptomatic Infection given Any Infection	Relative probability of transitioning from Exposed to Presymptomatically Infected (rather than to Asymptomatically Infected)
P _{IS IP, i}	Protection against Severe Infection given Symptomatic Infection	Relative probability of transitioning from Mildly Infected to Severely Infected (rather than recovering)
B _{on time, i}	Boosting on time	Whether the agent has received/will receive a booster shot $T_{V2\rightarrow B} = 5$ months after the second shot of their primary series (if any)
$V_{ m i}$	Vaccination status	Eligibility for future shots
Ii	Infection status	Transmissibility; hospitalization; progression, death, and recovery
t _{tested, i}	Most recent time tested, if any	Priority for future testing
t _{Q,i}	Time isolated	Eligibility for deisolation
Q_i	Isolation status	Eligibility for deisolation, presence or absence at work and, if applicable, shared housing (and hence, potential to transmit)

1378

Symbol	Definition (unit)	Possible values	Default value	References and Notes
Ν	Total number of agents (employee)	Farm: ≥4 Facility: ≥7	103	From user input (Table S11)
$N_{ m E}$	Initial number of agents who are in the Exposed state (E) (employee)	1–N	1	Assumed
$N_{\rm IM}$	Initial number of agents with Mild COVID-19 symptoms (employee)	$0 - (N - N_{\rm E}(0))$	0	Assumed
$f_{ m R}$	Initial proportion of agents who have recovered from COVID-19 infection within the past $T_{RQ} = 1$ year (including those who were not symptomatic) (unitless)	0%-100%	69%	(32, 34, 35) (Derivation in Text S10)
fv2	Initial proportion of agents who are fully vaccinated as part of the primary series of a COVID-19 vaccine (e.g., 2 shots of Pfizer) (unitless)	0%-100%	71%	(32, 33) (Derivation in Text S10)
$f_{\rm V2,\ recent}$	Initial proportion of agents who have become fully vaccinated within the past $T_{V2\rightarrow B} = 5$ months (unitless)	0%-f _{V2} %	9%	(32, 33) (Derivation in Text S10)
fв	Of agents who are eligible to receive a booster shot (i.e., have completed their primary series of COVID-19 vaccination at least $T_{V2\rightarrow B}$ ago), initial proportion who have received a booster shot (unitless)	0%-100%	45%	(<i>32</i> , <i>33</i>) (Derivation in Text S10)
$f_{ m B,recent}$	Of agents who are eligible to receive a booster shot, fraction who have received a booster shot within the past $T_{V2\rightarrow B}$ (unitless)	0%-f _B %	45%	(32, 33) (Derivation in Text S10)
Т	Number of days to simulate (day)	30-150	90	
Η	Employee housing type (categorical)	"Shared" or "Individual"	Farm: "Shared" Facility: "Individual"	
R _{0,housing}	Contribution of (expected) transmissions in shared housing to R_0 for a given level of physical distancing (High", "Intermediate", or "Low") (unitless)	"High": 1, "Intermediate" : 2, or "Low": 4	2	When housing is "Shared"
λ	Daily force of infection from sources outside of the workforce of the operation modeled for a given level of physical distancing ("High", "Intermediate", or "Low") (employee ⁻¹ day ⁻¹)	"High": 0.02, "Intermediate" : 0.002 or "Low": 0.00002	0.002	When housing is "Individual"
R _{0,work}	Contribution of work transmissions to (homogeneous) R ₀ for a given level of physical distancing (High", "Intermediate", or "Low") (unitless)	"High": 4, "Intermediate" : 6, or "Low": 8	6	Based on physical distancing to/at work
$n_{\rm w,c}$	Number of field workers per crew (excluding foreman) (employee)	1-100	10	Farm specific
n _{c,s}	Number of crews per supervisor (employee)	1-100	3	Farm specific
ns	Number of supervisors (employee)	1-100	3	Farm specific
$D_{ m weekly}$	Total production value per week (default defined by employee number) (US \$)	0-1,000,000	247,612	Farm specific
W	Average hourly wage of a worker (US \$)	1-100	13.89	Farm specific
$n_{ m w,l}$	Number of workers per production line (employee)	2-100	10	Facility specific
n_1	Number of production lines (lines)	1-100	3	Facility specific
$n_{\rm sh}$	Number of production shifts (employee)	1 or 2	2	Facility specific
$n_{\rm cs}$	Number of cleaning shift workers (employee)	2-100	10	Facility specific
$n_{\rm fsh}$	Number of floating workers in a production shift	1-100	10	Facility specific

1379 Table 2. User-settable model parameters

(employee)	fic
	fic
$n_{\rm f,all}$ Number of workers that may be present across 1-100 11 Facility specific	
shifts (including manager) (employee)	
D_{week} Total production value per week (default defined 1-10,000,000 784,346.67 Facility specific	fic
by employee number) (US \$)	
$H_{\rm W}$ Average hourly wage of a production line worker 1-100 16.57 Facility specific	fic
(US \$)	
<i>F</i> Indoor facility size (for estimation of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of a 1-100,000 1,000 Facility specified of the cost of the cost of the cost of a 1-100,000 1,000 Facility specified of the cost o	fic
HEPA air cleaner) (sq ft)	

1380

Table 3. Numbers of agents with various immune states and histories derived from user-set

parameters. Additional details, including the equations for the calculation of *N* from userset parameters, can be found in **Text S2** and **Table S2**. In the rightmost column, equations are presented for how past event times ($t_{R, i}$, $t_{V2, i}$, and/or $t_{B, i}$, as applicable and relevant) and boosting status or "intention" ($B_{on time, i}$) are set for individuals encompassed in each of the described counts. As some of these counts are nested within other counts (e.g, $N_{B, recent}$ within N_B within $N_{V2, older}$), these attribute distributions are specified at the highest level for each they are consistent. For individuals who have received the second dose of their two-dose primary vaccination series at least $T_{V2\rightarrow B}$ ago, $B_{on time, i}$ indicates whether that individual *received* a booster dose "on time" when they became eligible to receive one (i.e., $T_{V2\rightarrow B}$ after the second dose of their primary series). For individuals who have completed their primary series less than $T_{V2\rightarrow B}$ ago, or who have not completed their primary series at all, it indicates whether they *will receive* a booster dose "on time," if and when they become eligible to receive one.

Symbol	Description	Value	Associated equation(s), for an agent <i>i</i> who is part of this count
N	Total number of agents (employee)	Farm: ≥4 Facility: ≥7	
$N_R(0)$	Number of agents who have recovered from natural infection within the last year before the simulation start	round($N * f_{\rm R}$)	$t_{\rm R,i} \sim {\rm Uniform}(-{\rm T}_{\rm RQ},0)$
N _{V2} (0)	Number of agents who have completed a course of primary vaccination at simulation start	round($N * f_{V2}$)	
Nv2, recent(0)	Number of agents who have completed a course of primary vaccination <i>less than</i> $T_{V2\rightarrow B} = 152$ days (5 months) prior to the start of simulation	round($N * f_{V2, recent}$)	$t_{V2, i} \sim \text{Uniform}(-T_{V2 \rightarrow B}, 0)$ $B_{\text{on time, i}} \sim \text{Bernoulli}(f_B)$
Nv2, older(0)	Number of agents who have completed a course of primary vaccination <i>more than</i> $T_{V2\rightarrow B}$ prior to the start of simulation	$N_{\rm V2}(0)$ - $N_{\rm V2, recent}(0)$	
$N_B(0)$	Number of agents who have received a booster dose	$f\mathbf{B} * N_{V2, older}$	$B_{\rm on time, i} = 1$
$N_{B, recent}(0)$	Number of agents who have received a booster dose <i>less than</i> $T_{V2 \rightarrow B}$ prior to the start of simulation	$f_{ m B, recent} * N_{ m V2, older}$	$t_{V2, i} \sim Uniform(-2 * T_{V2 \rightarrow B}, -T_{V2 \rightarrow B})$ $t_{B, i} = t_{V2, i} + T_{V2 \rightarrow B}$
$N_{B,older}(0)$	Number of agents who have received a booster dose <i>more than</i> $T_{V2\rightarrow B}$ prior to the start of simulation	$N_{ m B}(0)$ - $N_{ m B, recent}(0)$	$t_{V2, i} \sim \text{Uniform}(-T_{1\text{st }V2} \rightarrow 0, -(2 * T_{V2 \rightarrow B} + 1))$ $t_{B, i} = t_{V2, i} + T_{V2 \rightarrow B}$
Nv2,older,no booste r	Number of agents who have completed a course of primary vaccination <i>more than</i> $T_{V2\rightarrow B}$ prior to the start of simulation but have <i>not</i> received a booster (despite presumably being eligible)	$N_{ m V2,older}$ - $N_{ m B}(0)$	$t_{V2, i} \sim \text{Uniform}(-T_{1st \vee 2} \rightarrow 0, -T_{V2 \rightarrow B})$ $B_{\text{on time, } i} = 0$
N _{no V2}	Number of agents who have not completed a primary course of vaccination	N - N _{V2}	$B_{\text{on time, i}} \sim \text{Bernoulli}(f_{\text{B}})$

- 1381 1382
- 1383
- 1384

1385

1386

Table 4. Selected sensitivity parameters and derived distributions. Gamma distributions are 1387 notated Gamma(shape, scale); when the mean is varied in sensitivity analysis, this is done 1388 by varying the scale parameter, while holding the shape parameter fixed. For more details, 1389 see **Text S9**. In the case of β_{IM} , it is the ratios between β_{IM} and the corresponding 1390 parameters for asymptomatic and presymptomatic infection (β_{IA} and β_{IP}) that are taken 1391 from Moghadas et al. 2020 (51); the absolute magnitudes are rendered irrelevant by how 1392 we set contact rates. The derivation of coefficients for logistic decay formulas (including 1393 1394 the conversion from rates per month to rates per day) is in Text S11. The selected value for parameter ψ is towards the high end of a range of estimates, as a precautionary 1395 measure given significant uncertainty (56)1396

Symbol	Definition	Formula/value	Reference
D _{IP, i}	Duration of Presymptomatic Infection	Gamma(1.058, 2.174)	(51)
$D_{ m E+IP,i}$	Incubation Period (time from infection to symptoms; model	max(Lognormal(1.65,	(51)
	structure implies that this must be \geq latent period)	$0.0192), D_{\rm IP,i})$	
$D_{ m E,\ i}$	Duration of Exposed stage (Time from infection to	$D_{ m E+IP,\ i}$ - $D_{ m IP,\ i}$	
	infectiousness, i.e., latent period)		
D _{IA, i}	Duration of Asymptomatic Infection	Gamma(5, 1)	(51)
D _{IM, i}	Duration of Mildly symptomatic Infection	Gamma(16, 0.5)	(55)
D _{IS, i}	Duration of Severely symptomatic Infection	Gamma(34.0278, 0.4114)	(55)
D _{IC, i}	Duration of Critically symptomatic Infection	Gamma(34.0278, 0.4114)	(55)
μ_{IM}	Mean duration (shape * scale) of mildly symptomatic infection.	8	(55)
$\beta_{\rm IM}$	Relative per-contact transmissibility during Mild infection (unitless)	0.0253	(51)
φ	Parameter controlling the relative magnitude of protection from symptomatic disease given infection, and protection from severe disease given symptoms, from natural and hybrid immunity (details in Text S3B)	0.5	Assumption
a _{R, IS}	Constant coefficient in logistic decay formula for overall Protection from Severe Infection granted by natural immunity	1.70512	(53)
b _{R, IS}	Time-dependent coefficient (1/days) in logistic decay formula for overall Protection from Severe Infection granted by natural immunity	-0.05211/30.5 = -0.00170852459	(53)
$a_{\mathrm{R,E}}$	Constant coefficient in logistic decay formula for Protection from Any Infection granted by natural immunity	1.2100	(53)
$b_{ m R,E}$	Time-dependent coefficient (1/days) in logistic decay formula for Protection from Any Infection granted by natural immunity	-0.1937/30.5 = -0.00635081967	(53)
ψ	Relative frequency of severe infection, in the absence of any immunity, for the (original) Omicron strain relative to 2020 strains	1.2	(56)
$T_{\rm ramp, RH}$	Interval from beginning of ramp-up of natural or hybrid immunity (if applicable) to achieving maximum protection	1 month (30.5 days)	(53)
$T_{\text{total}, R}$	Interval of complete protection following natural recovery	2 months (61 days)	(53)
$T_{\rm V2 \rightarrow B}$	Minimum interval between completion of primary series and booster dose	5 months (152 days)	(54)
$T_{1 { m st V2}} > 0$	Number of days since the first individuals in the US received the secondary dose of their primary vaccine series, at the start of simulation	1 year, 61 days (426 days)	(54)
T _{RQ}	Period for which the user is asked to supply the fraction of workers who have recovered from natural infection in the past [duration]	1 year (365 days)	

1398 Supplementary Materials

- 1399
- 1400 Supplementary Materials enclosed.
- 1401